Investigating The Role Of Dna Polymerase Beta In The Aging Phenotype Of Down Syndrome by Ahmed, Aqila Ahmed
Wayne State University
Wayne State University Dissertations
1-1-2016
Investigating The Role Of Dna Polymerase Beta In
The Aging Phenotype Of Down Syndrome
Aqila Ahmed Ahmed
Wayne State University,
Follow this and additional works at: https://digitalcommons.wayne.edu/oa_dissertations
Part of the Medicine and Health Sciences Commons, and the Molecular Biology Commons
This Open Access Dissertation is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in
Wayne State University Dissertations by an authorized administrator of DigitalCommons@WayneState.
Recommended Citation
Ahmed, Aqila Ahmed, "Investigating The Role Of Dna Polymerase Beta In The Aging Phenotype Of Down Syndrome" (2016). Wayne
State University Dissertations. 1617.
https://digitalcommons.wayne.edu/oa_dissertations/1617
 INVESTIGATING THE ROLE OF DNA POLYMERASE BETA IN THE AGING 
PHENOTYPE OF DOWN SYNDROME 
 
by 
AQILA A. AHMED 
DISSERTATION 
Submitted to the Graduate School 
of Wayne State University, 
Detroit, Michigan 
in partial fulfillment of the requirements 
for the degree of 
DOCTOR OF PHILOSOPHY 
2016 
         MAJOR: NUTRITION AND FOOD SCIENCE 
  Approved By: 
___________________________________ 
    Advisor                         Date 
____________________________________ 
____________________________________ 
____________________________________ 
 
 
 
 
 
ii 
  
DEDICATION 
 
I dedicate this thesis to my amazing little boy, Jacob. 
 
Our passion for learning ... is our tool for survival. -Carl Sagan 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
  
ACKNOWLEDGMENTS 
I would like to express my sincere gratitude and appreciation to my PhD advisor, Dr. 
Diane C. Cabelof. This journey would not have been this rewarding or enjoyable without her 
guidance. She pushed me to excel not only in research but also in life. I have gained a lifelong 
mentor and friend.  
Many thanks to my committee members Drs. Ahmad  Heydari, Michael Tanisky, and 
Yifan Zhang for their time and willingness to serve on this committee. I want to thank all the 
past and present members of Cabelof lab. I especially would like to thank Kirk Simon and 
Cristine Smoczer. I was lucky to gain not only knowledge and skills but also the friendship of 
kind, sincere and overall amazing people.  I would like to give thanks to all the fellow PhD 
students in NFS department (Kasia, Hoda, Varun, Wenjun, Khadijah, Sarah, and Jiangqi). I want 
to thank all my friends for the support over the years. Alina, Aida, Mirela, Melina and Denise are 
more like sisters than friends. From selfies to parties and from heartbreak to loneliness, thanks 
for being there for me through it all.  
I want to thank my parents (Ali and Zaboon) for the support and encouragement (and free 
babysitting). Without you I would not have been able to finish this degree.  I want to thank my 
sisters ( Saqia, Hamida, Hailah and Marym), who have been  my biggest cheerleaders.  
 
 
 
 
 
 
iv 
  
TABLE OF CONTENTS 
Dedication   ..................................................................................................... ..................................... ii 
Acknowledgments ................................................................................................................................ iii    
List of Tables ...................................................................................................... ................................ vi 
List of Figures………..................................................... .................................................................... vii 
List of Abbreviations ............................................................................................................................ ix 
Chapter 1: Introduction 
 A. Down syndrome (DS) ..................................................................................... ................... 1 
 B.  Senescence/premature aging ............................................................................................... 3 
 C.  Oxidative stress ................................................................................................................... 5 
 D. DNA repair capacity ............................................................................................................ 8  
            F. Micro-RNA 155 .................................................................................................................. 13 
Chapter 2: Loss of DNA Polymeraseβ Induces Senescence: Implications in  
Down Syndrome 
 
A. Summary ........................................................................................................................... 20 
B. Intro ................................................................................................................................... 21 
C. Methods And Materials .................................................................................................... 23 
D. Results ............................................................................................................................... 25 
E. Discussion ......................................................................................................................... 28 
Chapter 3: Regulation of DNA Polymeraseβ by miR-155 
A. Summary ........................................................................................................................... 39 
B. Intro ................................................................................................................................... 40 
C. Methods and Materials ..................................................................................................... 41 
v 
  
D. Results ............................................................................................................................... 47 
E. Discussion ......................................................................................................................... 50 
CHAPTER 4: Ts65Dn Mouse Model  
A. Summary………………………………………………………….. .............................. 61 
B. Intro ................................................................................................................................... 61 
C. Methods and Materials ..................................................................................................... 69 
D. Results ............................................................................................................................... 71 
E. Discussion ......................................................................................................................... 74 
Chapter 5: Discussion And Future Direction ................................................................................ 101 
References ......................................................................................................................................... 106 
Abstract .............................................................................................................................................. 135 
Autobiographical Statement  ............................................................................................................. 136 
 
 
 
 
 
 
 
 
 
 
 
vi 
  
LIST OF TABLES 
Table 1.2: Pathophysiological and cellular criteria of ageing ............................................................ 16 
Table 1.3: Genes on chromosome 21 implicated in oxygen metabolism .......................................... 17 
Table 2.1: Quantitative RT-PCR Primer sequences ........................................................................... 31 
Table 3.1: Primer sequences ............................................................................................................... 53 
Table 3.3.5 Validated miR-155 targets shown in our dataset ............................................................ 59 
Table 3.3.6: Impact of miR-155 overexpression on proteins involved in DNA repair  .................... 60 
 
Table 4.2:  Summary of segmental trisomy mouse models and features of  
 Down Syndrome that have been documented in each model ................................................ 76 
 
Table 4.3:  Summary of transgenic Mouse models ............................................................................ 77 
Table 4.4: Primer sequences ............................................................................................................... 78 
Table 4.7.1: Summary of Segmental trisomy Mouse models .......................................................... 100 
 
 
 
 
 
 
 
 
 
 
 
 
vii 
  
LIST OF FIGURES 
Figure 1.1: Nondisjunction ................................................................................................................. 16 
Figure 1.4: Base Excision Repair pathway ......................................................................................... 19 
Figure 2.1: Primary Down syndrome fibroblasts exhibit gene dosage effects  
 for oxidative stress response genes on chromosome 21 ........................................................ 32 
 
Figure 2.2: Premature cellular senescence in Down syndrome fibroblasts.  
 A. Down syndrome fibroblasts exhibit a premature senescence phenotype.  
 B. Down syndrome fibroblasts exhibit an amplified senescence response 
 to hydrogen peroxide and HU ................................................................................................ 33 
 
Figure 2.3: Primary Down syndrome fibroblasts exhibit reduced DNA  
 Polymerase β transcript abundance ........................................................................................ 34 
 
Figure 2.4: Homozygous loss of DNA polymeraseβ induces premature  
 cellular senescence. A. Loss of DNA polymeraseβ is sufficient to induce  
 senescence. B. DNA polymeraseβ null mouse embryonic fibroblasts  
 exhibit an amplified senescence response to hydroxyurea .................................................... 35 
 
Figure 2.5: DNA polymeraseβ protects cells from hydroxyurea-induced 
  DNA double strand breaks. A. DNA polymeraseβ is upregulated  
 in response to hydroxyurea. B. Loss of DNA polymeraseβ induces  
 DNA double strand breaks ....................................................................................................  36 
 
Figure 3.1: Proposed model of  Polβ by miR-155 ............................................................................. 39 
Figure 3.2 SILAC-based quantitative proteomics.  Flowchart of double  
 SILAC coupled with LC-MS/MS  ......................................................................................... 54 
 
Figure 3.3.1: Ectopic overexpression of miR-155 in MEFs .............................................................. 55 
Figure3.3.2: Validation of C/EBP β downregulation in miR-155 ..................................................... 56 
Figure 3.3.3: Polβ transcript and protein expression is downregulated in  
 miR-155 Cells ........................................................................................................................  57 
 
Figure 3.3.4:Polβ  Promoter activity is inhibited by miR-155 overexpression ................................. 58 
Figure 4.1:  Major Mouse Models of Trisomy 21 .............................................................................. 76 
Figure 4.6.0: Ts65Dn are smaller than WT controls .......................................................................... 79 
Figure 4.6.1: Liver wet weights in Ts65dn (DS) and WT (NDS) ....................................................  80 
viii 
  
Figure 4.6.2: Weight of Lung in three cohorts ................................................................................... 81 
Figure 4.6.3: Ts65Dn mice have underdeveloped Testes .................................................................. 82 
Figure 4.6.4: Kidney weight did not differ ......................................................................................... 83 
Figure 4.6.5: Ts65Dn heart is  smaller than WT ................................................................................ 84 
Figure 4.6.6: No difference was seen in Brain weight ....................................................................... 85 
Figure 4.6.7: PolB expression in Ts65Dn mice tissues at 16 week ................................................... 86 
Figure 4.6.8:  PolB expression in Ts65Dn mice tissues ..................................................................... 87 
Figure 4.6.9: PolB expression in Ts65Dn mice tissues ...................................................................... 88 
Figure 4.6.10 : PolB expression in Ts65Dn Skin ............................................................................... 89 
Figure 4.6.11: p16 expression in Ts65Dn Tissues ............................................................................. 90 
Figure 4.6.12 : p16 expression in Ts65Dn Tissues ............................................................................ 91 
Figure 4.6.13: p16 expression in Ts65Dn Tissues ............................................................................. 92 
Figure 4.6.14: p16 expression in Ts65Dn Tissues ............................................................................. 93 
Figure 4.6.15: p16 expression in Ts65Dn Tissues ............................................................................. 94 
Figure 4.6.16: p16 expression in Ts65Dn Tissues ............................................................................. 95 
Figure 4.6.17: Incidence of lymphoma in Ts65Dn Spleen ................................................................ 96 
Figure 4.6.18: Incidence of malignant tumors of lung in Ts65Dn .................................................... 97 
Figure 4.6.19: Incidence of lymphoma in stomach of Ts65Dn ......................................................... 98 
Figure 4.6.20: Incidence of lymphoma in Intestine of Ts65Dn ......................................................... 99 
Figure 5.1.1: The proposed mechanism by which miR-155 regulates PolB ................................... 104 
 
 
 
ix 
  
LIST OF ABBREVIATIONS 
DS-Down syndrome 
HSA21- Human chromosome 21 
miR-microRNA  
SOD1- superoxide dismutase 1 (Cu-Zn 
BACH1- BTB Domain And CNC Homolog 1) 
PolB/POLB- DNA polymerase beta 
Creb1/CREB1- Cyclic AMP-responsive element-binding protein 1 
MMS- methane methylsulfonate  
BER- Base excision repair 
RT-PCR- real time polymerase chain reaction 
MEF- mouse embryonic fibroblast 
WT- wild type 
C/EBP β- CCAAT/enhancer-binding protein beta 
AD- Alzheimer disease 
ROS- reactive oxygen species 
NAD- Nicotinamide adenine dinucleotide 
SA- β-gal -Senescence-Associated β-Galactosidase  
APP -β-amyloid precursor protein 
TTFs -terminal-tip fibroblasts  
CAT -catalase  
GPx  -glutathione peroxidase  
HO-1-downregulates heme oxygenase-1  
x 
  
UDG - uracil DNA glycosylase  
APE1- Apurinic/apyrimidinic endonuclease  
XRCC1- X-Ray Repair Complementing Defective Repair In Chinese Hamster Cells 1 
PCNA - Proliferating cell nuclear antigen 
PARP1- Poly(ADP-Ribose) Polymerase 1 
SP-BER -short patch BER  
MNNG- Methylnitronitrosoguanidine 
MN- micronucleus formation  
DSB- double strand breaks 
SSB- single strand break 
DSCR1-Down Syndrome Critical Region 1  
BrdU- 5-bromo-2'-deoxyuridine 
DDR -DNA damage response  
MMR- Mismatch repair 
HR – homologous repair  
NHEJ- non-homologous end joining 
FOXO3a- Forkhead box O3 a 
 
 
 
 
 
 
1 
 
 
CHAPTER 1: INTRODUCTION 
A. Down syndrome (DS) 
Down syndrome (DS) is one the most common genetic disorders in the US, with 400, 000 
Americans living with DS and 6,000 babies born with DS each year (S. E. Parker et al., 2010). 
DS is a condition in which the affected individual has a full or partial extra copy of chromosome 
21 (Trisomy 21).  John Langdon Down first described the condition in 1866, while the 
underlying cause for it was discovered by Jerome Lejeune in 1959.   Ninety five percent of DS 
cases are caused by an error in cell division during either meiosis I or meiosis II, when an 
embryo receives three copies of chromosome 21 instead of two. This meiotic division error is 
commonly known as trisomy 21, a form of chromosomal nondisjunction. The extra chromosome 
is then replicated in every cell of the body unlike the mosaic trisomy (5%), where triplicated 
Hsa21 is only found in certain tissues.  Chromosome 21 is the smallest human chromosome, 
spanning about 48 million base pairs and representing 1.5 -2% of the total DNA in a cell. 
Chromosome 21 contains 200 - 300 known protein-coding genes involved in a wide range of 
processes.  
Individuals with DS suffer from both physical and cognitive disabilities (Table 1.1).  
Common conditions seen in people affected with Down syndrome are: altered immune system 
function, muscular hypotonia, dysmorphic otolaryngologic features, and premature aging 
(Esbensen, 2010; Patterson & Cabelof, 2012; Roth, Sun, Greensite, Lott, & Dietrich, 1996; 
Scoggin & Patterson, 1982; Shin et al., 2009; Shott, 2006; Zigman, Schupf, Lubin, & Silverman, 
1987). These individuals are highly susceptible to infections, particularly of the respiratory and 
the gastrointestinal tract. Congenital heart defects are seen in almost 50% of DS newborns (Shin 
et al., 2009) and many, even without congenital heart defects, develop mitral valve disease. 
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Nearly 50% of DS individuals have hypothyroidism and about 20% celiac disease. Obstructive 
sleep apnea syndrome occurs in approximately half of the cases (Shott 2006). DS individuals 
have  high prevalence of obesity during childhood and adolescence (van Gameren-Oosterom et 
al., 2012).  Sensori-neural hearing loss and cataract may develop before the age of 30 (Shott 
2006). Behavioral changes with loss of skills, withdrawal, psychomotoric retardation, and 
mutism occur frequently from the age of 30 and may represent either symptoms of mental illness 
or onset of Alzheimer's dementia (Hill et al., 2003; Levine, Saltzman, Levy, & Ginsberg, 2009; 
Lott, 1982; Odetti et al., 1998; Qureshi & Parvez, 2007; Rabinowe, Rubin, George, Adri, & 
Eisenbarth, 1989; Scoggin & Patterson, 1982; Shin et al., 2009; Zigman et al., 1987) By the age 
of 40, virtually all individuals with DS  will have neuropathology of AD (Head, Powell, Gold, & 
Schmitt, 2012). 
To dissect the pathogenesis of DS, two hypotheses have been proposed:  the amplified 
developmental instability hypothesis and the gene-dosage effect hypothesis (Pritchard & Kola, 
1999).The amplified developmental instability hypothesis advocates that a non-specific 
disturbance of the chromosomal balance leads to development homeostasis disruption (Pritchard 
& Kola, 1999; N. Rueda, Florez, & Martinez-Cue, 2012). This hypothesis states that the features 
of DS are likely due to the overall abundance of genetic material and not to specific genes.  
The gene-dosage effect hypothesis suggests that the HSA21 trisomy causes a general 
alteration in developmental homeostasis that leads to the DS phenotypes (Pritchard & Kola, 
1999).  It states that these alterations result from overexpression of a subset of genes located in 
the critical region on chromosome 21 (Greber-Platzer, Schatzmann-Turhani, Wollenek, & Lubec, 
1999).  Genes implicated in oxidative stress regulation have been shown to play key roles in the 
pathogenesis of DS.  This hypothesis aligns with the free radical theory of aging, which states 
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that energy consumption causes in time buildup of waste, such as ROS (Harman, 1981), which 
leads to constant attack on cells, causing them to cease proliferation and thus, age. Over the 
years, evidence of  the role of caloric restriction in longevity  has helped to support this theory 
(Heilbronn & Ravussin, 2003).   
Premature Aging  
DS exhibits many of the typical aging signs such as atrophy (skin thinning and loss of 
elasticity), loss of cutaneous fat, wrinkling, greying hair, and loss of hair ((Bittles & Glasson, 
2004; Brown, 1987; Esbensen, 2010; Franceschi et al., 1992; Gilchrest, 1981; Hill et al., 2003; 
Horvath et al., 2015; Lott, 1982; Murdoch & Evans, 1978; Patterson & Cabelof, 2012; Roth et 
al., 1996)). DS was first characterized as a segmental progeria in 1982 (Martin, 1982) and was 
found to be the only genetic disorder that had 14 of the 17 features of a true premature aging 
syndrome, according to Martin (Table 1.2) (Martin 1977).  In the early 1900s, the life expectancy 
of DS individuals was about 12 years of age (Carmeli, Kessel, Bar-Chad, & Merrick, 2004). By 
1983 it was 35 years, an increase accredited to improvements in medical care for both children 
and adults (Head et al., 2012). Current life expectancy for a one year old with DS is 43-55 years 
(Uppal, Chandran, & Potluri, 2015). The shortened  lifespan is said to be due to  DS mortality 
rate doubling every 6.4 years , as compared to every 9.6 years for the rest of the population 
(Head et al., 2012).   
Evaluating in vitro aging/senescence of cultured fibroblasts is widely utilized as a 
surrogate model for in vivo aging.  Segal and McCoy were first to show that DS  fibroblasts  had 
a slower growth rate and  decreased life span (Segal & McCoy, 1974).  Chapman et al  showed 
that NAD levels and proliferation ability were altered in DS lymphocytes and fibroblasts 
(Chapman, Zaun, & Gracy, 1983).  The senescence phenotype of DS has been confirmed in 
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human tissue and mouse DS models (Chapman et al., 1983; Contestabile, Fila, Cappellini, 
Bartesaghi, & Ciani, 2009; Fuchs, Ciani, Guidi, Trazzi, & Bartesaghi, 2012). The immune 
dysfunction seen in DS has been linked to the early senescence of immune system, as 
characterized by small thymus and abnormal lymphocytes (S. S. Agarwal et al., 1970; da Rosa 
Utiyama et al., 2008; Rabinowe et al., 1989).  Utilizing proliferation marker Ki-67, Contestabile 
et al showed a reduced number of proliferating cells in the hippocampal dentate gyrus and in the 
neocortical germinal matrix of fetuses with Down syndrome. A well-known method to assess 
senescence is the Senescence-Associated β-Galactosidase (SA- β-gal), which relies on the 
detection of beta galactosidase at pH =6 (Dimri et al., 1995; Itahana et al., 2003). This enzyme is 
specifically produced by senescent cells only and is not observed in quiescent or transformed 
cells (Dimri et al., 1995). Fibroblasts collected from DS donors are positive for SA-β-Gal in 
higher numbers than controls (Rodriguez-Sureda, Vilches, Sanchez, Audi, & Dominguez, 2015). 
Two other established markers of senescence, p16Ink4a and p19Arf, are involved in senescence-
induced loss of proliferation and have been shown to be overexpressed in DS (Adorno et al., 
2013; Baker et al., 2011; Itahana et al., 2003; Y. Liu et al., 2009; Yeo et al., 2000).  
 Similar findings were seen in a widely used mouse model of DS, Ts65dn. Ts65Dn model 
phenocopies much of DS, even though it is trisomic for only about 60% of the HSA21 genes. 
Mouse embryonic fibroblasts (MEFs) and terminal-tip fibroblasts (TTFs) from this model 
showed a high number of  SA-β-Gal-positive cells and increased p16Ink4a expression (Adorno 
et al., 2013; Contestabile et al., 2009). Interestingly, the reduced proliferation in Ts65Dn is 
widespread as multiple tissues were affected (heart, liver, skin and intestine) and appears early in 
life (postnatal) (Contestabile et al., 2009; Contestabile et al., 2007). More work is needed to fully 
evaluate the accelerated aging phenotype of this model. 
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 Alzheimer’s disease (AD) is considered a disease of old age, with increasing risk for 
individuals over 65 years (Head et al., 2012). It is the most common cause for dementia and 
overall cognitive decline (Larson, Kukull, & Katzman, 1992).  AD neuropathology appears in 
virtually all DS adults older than 40 years of age (Head et al., 2012). DS individuals have early 
AD onset , some showing signs in their 30s (Head et al., 2012; Hill et al., 2003; Jackson, 
Holland, Williams, & Dickerson, 1988). AD is a major cause of mortality in DS, third to 
congenial defects and leukemia (Esbensen, 2010; Hermon, Alberman, Beral, & Swerdlow, 2001; 
Hill et al., 2003; Uppal et al., 2015; Q. Yang, Rasmussen, & Friedman, 2002). AD risk has been 
attributed to β-amyloid precursor protein (APP), which is encoded on chromosome 21. The extra 
chromosome leads to overexpression of APP and thus, to generation of shortened β-amyloid 
(Aβ) peptides that cause senile plaques (Head et al., 2012)  Another DS trait responsible for 
increased AD risk is the highoxidative stress(Head et al., 2012).  
B. Oxidative Stress 
Oxidative stress is considered one of the main causes of aging and DS provides the best 
evidence for this hypothesis. DS is a disorder characterized by constitutive oxidative stress, 
which causes damage to DNA, lipid and protein oxidation (Amparo Gimeno et al., 2014; Odetti 
et al., 1998; Praticò et al., 2000; Marianna Zana, Janka, & Kálmán, 2007; M. Zana et al., 2006). 
This is likely due to the presence of many genes on HSA21 that are involved in regulation of 
oxygen metabolism (See Table 1.3) (Patterson & Cabelof, 2012).   
One of the best studied enzymes is superoxide dismutase 1 (Cu-Zn), SOD1.  SOD1 is 
encoded on the distal portion of HSA21 and  is responsible for destroying free superoxide 
radicals by converting them to hydrogen peroxide (H2O2) (F. L. Muller, M. S. Lustgarten, Y. 
Jang, A. Richardson, & H. Van Remmen, 2007).  The ~ 50% overexpression of SOD1 in DS, 
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without a coordinated upregulation of the two downstream enzymes, catalase (CAT) and 
glutathione peroxidase (GPx),  causes an abundance of H2O2, which leads to hydroxyl radical 
damage (Campos & Casado, 2015; de Haan, Cristiano, Iannello, & Kola, 1995; Druzhyna, Nair, 
LeDoux, & Wilson, 1998; A. Gimeno et al., 2014; Kedziora & Bartosz, 1988; Patterson & 
Cabelof, 2012). In addition, when SOD1 is overexpressed in human neuroblastoma cell line, the 
proliferation rate was reduced by 30% compared to untransfected cells (Lee, Hyun, Jenner, & 
Halliwell, 2001). The increased activity of SOD1 also underlies the neural abnormalities 
observed in individuals with Down syndrome (de Haan et al., 1995; Lee et al., 2001; Zitnanova 
et al., 2004). Other DS traits attributed to SOD1 overexpression were demonstrated in transgenic 
mouse models overexpressing SOD1.  In three independently derived transgenic SOD1 mice, 
overexpression caused thymus and bone marrow abnormalities similar to those seen in DS 
(Peled-Kamar, Lotem, Okon, Sachs, & Groner, 1995).  Another study showed that transgenic 
animals exhibited significant pathological changes in tongue neuromuscular junctions (NMJ) 
similar to those observed in the tongue muscle of patients with Down's syndrome (Groner et al., 
1990). 
For years, overexpression of SOD1 was thought to be the major cause of increased 
oxidative stress in DS.  Bach1, a transcription factor, acts as a repressor of oxidative stress 
response and was recently  implicated in DS pathogenesis (Domenico et al., 2015). Bach1 binds 
to antioxidant response elements (AREs) of DNA and inhibits transcription of specific genes 
involved in the cell stress response (Dohi et al., 2008). Thus, its overexpression can potentially 
play a role in the constitutive state of oxidative stress of DS. Bach1 was shown to be upregulated 
in the brain of DS individuals where it downregulates heme oxygenase-1 (HO-1)(Domenico et 
al., 2015). HO-1 is up-regulated in response to oxidative stress in order to protect cells against 
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ROS-induced damage and thus, its downregulation in DS brain could be a contributing factor to 
the early onset of Alzheimer's disease (Dohi et al., 2008; Domenico et al., 2015; Hefti, 
Quinones-Lombrana, Redzematovic, Hui, & Blanco, 2016).  
DS exhibits many makers of oxidation. In lipids, isoprostane 8,12-iso-iPF(2α)-VI is a 
specific marker of lipid peroxidation. Elevated levels of this isoprostane were found  in the urine 
of DS subjects compared with controls ((Praticò et al., 2000). DS neurons exhibit a three-fold 
increase in intracellular reactive oxygen species and show elevated levels of lipid peroxidation 
(Busciglio & Yankner, 1995). Protein oxidation is assessed by carbonyl assays (Marianna Zana 
et al., 2007), which measure the  amino acid oxidation by ROS. Cerebral cortices from DS 
fetuses, showed a 2.9 fold increase in carbonyl groups (M. Zana et al., 2006).  Using a 
proteomics approach, Perluigi et al showed that lipid peroxidation damages brain proteins by 
modify them and rendering them nonfunctional (M. Perluigi et al., 2009).  The accumulation of 
oxidation damage was shown to start very early, as evidenced by the presence of isoprostane in 
fetal liver (Cabelof et al., 2009). .   
ROS can cause multiple DNA modifications ranging from single base damage, single 
strand breaks, and double strand breaks.  Single base modifications  due to oxidative stress  
include: 8-oxoguanine (8-oxoG),  2,6-diamino-4-hydroxy-5-formamidopyrimidine (FapyG), and  
2,2- diamino-4-(2-deoxy-b-D-erythropentofuranosyl)amino]-5 (2H)-oxazolone (oxazolone, Oz) 
(Jena, 2012).  In fibroblasts from both adult and fetal DS samples, levels of 8-oxodG were 3-fold 
higher than in their matched controls (Necchi et al., 2015). Similar results were observed in 
brains of DS individuals (Domenico et al., 2015).  Numerous studies have shown an overall 
increase in DNA damage in DS samples. In one study, DS lymphocytes showed twice as much 
constitutive DNA damage in G2 over control  (Pincheira, Romero, Marcelain, Salazar, & de la 
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Torre, 2007)  A recent study showed that DS patients had significantly higher DNA damage, as 
assayed by comet assay (El-Bassyouni et al., 2015).  
DNA repair capacity  
Maintaining the integrity of DNA is vital for cell survival. There are numerous pathways 
that facilitate repair of damaged DNA. ROS are considered a major source of spontaneous DNA 
damage. A few sources of oxidative stress in the cell include: lipid peroxidation (Campos & 
Casado, 2015; Praticò et al., 2000; Marianna Zana et al., 2007), oxygen radicals produced during 
cellular respiration(Perrone et al., 2007) , and increased release of amyloid beta-peptide (Aβ) 
(Marzia Perluigi & Butterfield, 2012). The primary DNA repair pathway responsible for repair 
of oxidative stress damage is  base excision repair (BER) (Figure 2). BER is responsible for the 
repair of single base or  gap lesions, including abasic sites, single-strand breaks, deamination and 
alkylation damage (Cabelof, 2007; Dianov et al., 2001; Horton, Baker, Berg, Sobol, & Wilson, 
2002; Krokan & Bjoras, 2013; Ochs, Sobol, Wilson, & Kaina, 1999; Sobol et al., 1996; Wilson 
et al., 2000; Xu, Herzig, Rotrekl, & Walter, 2008). BER can be classified as either short patch or 
long patch, depending on the number of nucleotides replaced (Figure 1.4). The excision repair is 
initiated by DNA glycosylases, enzymes which recognize and excise the damaged base (Krokan 
& Bjoras, 2013). They are grouped in two classes: mono-functional or bifunctional, based on the 
distinct biochemical mechanism by which they repair damage. There are 11 known human 
glycosylases, with overlapping substrates, able to recognize more than one type of DNA damage 
(Jacobs & Schär, 2012). Mono-functional glycosylases, such as uracil DNA glycosylase (UDG), 
excise the damaged base by nucleophilic attack of N-glycosylic bond, via an activated water or 
hydroxyl ion (Savva, McAuley-Hecht, Brown, & Pearl, 1995), without nicking the DNA 
backbone. The resulting abasic site (Lindahl, Ljungquist, Siegert, Nyberg, & Sperens, 1977) is 
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then processed by apurinic or apryrimidine (AP) endonucleases.  AP endonucleases (APE1) 
create nicks in DNA by β-elimination, to yield 3' OH adjacent to a 5’-dRP (Bailly & Verly, 
1988; Y. J. Kim & Wilson, 2012).  Bifunctional glycosylases possess AP lyase activity that 
allows them to nick the DNA in addition to excising the damaged base. These enzymes use the 
amino group of a lysine side chain as a nucleophile for base cleavage, forming a covalent Schiff-
base intermediate with the damaged DNA strand (Jacobs & Schär, 2012). The product of this 
reaction is a strand break with 3′-phosphate and 5′-OH ends that are later processed by Ape1 to 
create 3’-OH and 5’-phosphate.  DNA polymerase beta (POLB) is the next enzyme. The 5’-dRP 
flap produced by APE1 will be processed by the dRP-lyase activity of POLB, creating a 
5’phosphate. The polymerization activity of POLB will then add the correct base creating a 3’-
OH adjacent to the 5’-phosphate. The final step is DNA ligase sealing the DNA strands and 
completing the repair. XRCC1, PCNA and  PARP1, are also involved in the repair process, by 
working to recruit and coordinate proteins in the BER process. LIGIIIα, the DNA ligase used in 
short patch BER (SP-BER) requires XRCC1 for full activity (Y. J. Kim & Wilson, 2012).  
The rate limiting enzyme in this pathway is DNA polymerase beta (POLB). POLB is a 39 
kDa protein containing a 31 kDa nucleotidyl-transferase domain and an 8 kDa dRP-lyase 
domain. Both polymerization and dRp-lyase activity are crucial to efficiently complete the repair 
process (Srivastava et al., 1998). The generation of the dRP-flap is a function of repair initiation 
by DNA glycosylases. POLB is regulated by a TATA-less promoter and also lacks a CAAT box. 
The minimal promoter contains 3 SP1 sites and a cAMP-response element (Widen, Kedar, & 
Wilson, 1988). Promoter deletion studies have clearly established that the TGACGTCA 
palindrome is essential for β-pol induction by alkylating (MNNG) and oxidizing (H2O2) agents 
(Kedar, Widen, Englander, Fornace, & Wilson, 1991; Widen & Wilson, 1991). A precise 
10 
 
 
sequence including the CRE palindrome and flanking residues (7 on each side of the palindrome) 
is required for ATF/CREB binding. As such, proteins that bind to ATF/CREB sites in other 
genes do not recognize the POLB promoter (Widen & Wilson, 1991). In 1997, it was determined 
that CREB1 and ATF1 were the transcription factors required for CRE-mediated TPA activation 
of the POLB promoter (X. P. Yang, He, Rawson, & Wilson, 1997). Importantly, following 
MNNG treatment, CREB1 levels increased but ATF1 levels did not. Additionally, recombinant 
expression of CREB1 increased POLB expression, even in the absence of MNNG (Narayan, 
Widen, Beard, & Wilson, 1994) In addition to the CRE site, POLB promotor has functional 
binding elements for transcription factors Sp1 and NF-κB (Faumont et al., 2009; Narayan et al., 
1994; Pei et al., 2011). Three NF-κB  binding sites were identified on POLB promoter(Faumont 
et al., 2009). Only the proximal kappaB binding site (-211 to -199nt) was found cause activation 
upon viral factors release in EBV-infected cells. Sp1 binds to DNA at consensus GC-boxes 
(Narayan et al., 2000) and on POLB promoter it acts as a stabilizer of the transcription complex 
(Narayan et al., 2000).  HIV-1 transactivator protein Tat transactivation of POLB is dependent 
on Sp1 binding site on POLB promoter (Srivastava et al., 2001).  
Most experiments on PolB functionality were done in mouse models. Homozygous PolB 
null (PolB
-/-
) mice are embryonically lethal, while the heterozygous mice (PolB
+/-
) are viable and 
have been vital in elucidating the phenotype associated with PolB loss. Mouse Embryonic 
Fibroblast (MEFs) from PolB
-/-
 collected at day 14 of gestation have been cultured and show 
sensitivity to alkylating agents, MMS and MNNG, and oxidative stress(Horton et al., 2002; Ochs 
et al., 1999; Pascucci, Russo, Crescenzi, Bignami, & Dogliotti, 2005; Podlutsky, Dianova, 
Wilson, Bohr, & Dianov, 2001; Sobol et al., 1996). PolB
-/-
 MEFs not only have deficient repair 
phenotype but also have a higher mutation frequency post MMS treatment (Sobol et al., 2002). 
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Studies on the PolB
+/-
 mouse and cultured cells show that heterozygosity leads  to ~50% 
reduction of PolB transcript and protein(Cabelof et al., 2003). These cells exhibit a significant 
reduction in the ability to repair damage due to MMS as evidenced by increased mutation 
frequency (Cabelof et al., 2003). Tissues collected from PolB
+/-
  mouse  displayed higher levels 
of DNA single-Strand breaks as well as increased chromosomal aberrations as compared to 
control littermates (Cabelof et al., 2003). PolB
+/-
  mice also showed an accelerated  onset of age-
dependent lymphoma and accelerated rate of mortality (Cabelof, Ikeno, et al., 2006). The loss of 
BER and POLB as a driving factor in accelerated aging has been the basis for my thesis.  
The DNA repair capacity of various organisms and their rate of aging were first shown to 
be correlative by Hart and Setlow in 1974 (Hart & Setlow, 1974).  Since then, various studies 
have shown that the DNA repair capacity declines with age and it  might be underlying old age 
diseases (Brosh & Bohr, 2007; Brown, 1987; Bucholtz & Demuth, 2013; Cabelof, 2007; 
Cabelof, Ikeno, et al., 2006; Cabelof, Raffoul, et al., 2006; Carre & Pieau, 1979; Franceschi et 
al., 1992; Gilchrest, 1981; Hanaoka et al., 1983; Harman, 1981; Intano, Cho, McMahan, & 
Walter, 2003; Li, Mitchell, & Hasty, 2008; Martin, 1982; Florian L. Muller, Michael S. 
Lustgarten, Youngmok Jang, Arlan Richardson, & Holly Van Remmen, 2007; Murray, 1981; 
Qureshi & Parvez, 2007; Rao, Annapurna, & Raji, 2001; Sykora et al., 2015; Vyjayanti, Swain, 
& Rao, 2012; Weirich-Schwaiger, Weirich, Gruber, Schweiger, & Hirsch-Kauffmann, 1994; 
Weissman et al., 2007; Xu et al., 2008).  The brain is highly affected by a DNA repair decline 
with age (Sykora, Wilson, & Bohr, 2013), shown by increase of neurodegenerative diseases with 
age. Defective or lost BER is suspected to have a role in dementia related disease, such as 
Alzheimer’s (Sykora et al., 2015; Weissman et al., 2007). This reduction in repair capacity 
furthermore correlates with decrease in the enzymatic activity of PolB enzymatic and low protein 
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and mRNA levels (Cabelof et al., 2002; Kisby et al., 2010; Krishna et al., 2005; Rao et al., 2001; 
Rao, Vinay Kumar, Bhaskar, & Sripad, 1994; Subba Rao & Subba Rao, 1984).  
DS is characterized by accelerated aging and abundant evidence appoints toward a DNA 
repair defect as the driving force of this phenotype. Many of the premature aging syndromes 
have been linked to a defect in either DNA damage response or repair (Brosh & Bohr, 2007). 
Unlike the other premature aging diseases, which are monogenic, DS genotype makes the 
identification of critical DNA repair genes difficult, but not impossible. Reduced DNA repair 
had been demonstrated in people with DS by accumulation of DNA repair intermediates (strand 
breaks), increased chromosomal damage, and reduced repair capacity, as demonstrated by in 
vitro methods and/or by expression levels of key DNA repair genes. Leukocytes from individuals 
with DS contain more DNA strand breaks than leukocytes from control patients (Maluf & 
Erdtmann, 2001). The ability to repair single strand breaks induced by gamma irradiation is 
reduced by DS (Athanasiou, Sideris, & Bartsocas, 1980). These unrepaired strand breaks might 
be expected to induce chromosomal aberrations. Indeed, patients with DS exhibit higher baseline 
levels of micronucleus formation (MN) and greater induction of MN in response to mitomycin 
C, cyclophosphamide, and quercetin than their age-matched controls(Caria, Chaveca, & Rueff, 
2001). Further, the MN response to mitomycin C is significantly impacted by age in DS (Shafik, 
Au, & Legator, 1988). Chromosomal aberrations are greater in lymphocytes exposed to ionizing 
radiation from DS individuals than age-matched controls (Scarfi et al., 1990). Actual measures of 
DNA repair capacity in DS have been addressed by what are now considered crude methods in 
which thymidine incorporation provides an estimate of unscheduled DNA synthesis (i.e., DNA 
repair). By these methods, investigators have shown reduced ability to repair DNA in response to 
PHA stimulation (S. S. Agarwal et al., 1970) and MNNG exposure (Raji & Rao, 1998). 
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Interestingly, this loss of repair capacity is accelerated with advancing age in DS (Raji & Rao, 
1998). 
In support to the hypothesis of this thesis, Raji and Rao have shown that young DS 
individuals experience a 50% reduction in POLB activity (Raji & Rao, 1998). The aged DS 
individuals experience an even greater deficit in POLB activity. Additionally, the inducibility of 
POLB in response to DNA damaging agents is blunted in DS. Importantly, they showed no 
effect of DS on another DNA polymerase that is not involved in DNA repair (POLε) Since then, 
we have shown that down regulation of POLB starts in utero (Cabelof et al., 2009). DS fetal liver 
(a surrogate for the hematopoietic system) expresses reduced transcript, protein, and enzymatic 
activity of POLB (Cabelof et al., 2009).  These data support a connection between the DNA 
repair defect of DS and the BER pathway. As mentioned above, Trisomy 21 causes an 
abundance of ROS/oxidative stress, damaging lipids, proteins and DNA.  Typically damage 
caused by ROS is predominately repaired by BER, but this pathway is defective in DS. Is the 
lack of an adaptive response to oxidative stress in DS a curse or blessing?  Across age, sex, and 
racial groups, individuals with DS develop tumors less than one-tenth as often as expected (Hill 
et al., 2003), with the exceptions of childhood leukemia and testicular cancer. In DS, leukemia is 
a childhood cancer  initiated in utero, and thus likely unrelated to senescence. Testes resist the 
increased expression of senescence-related biomarkers that occurs with age (Krishnamurthy et 
al., 2004). It is hypothesized that the reduced DNA repair causes a shift towards senescence 
instead of tumorigenesis.  
microRNA-155 
What is the cause of POLB downregulation in DS? The  two proposed  hypotheses for 
DS pathogenesis, the amplified developmental instability and the gene-dosage effect hypotheses 
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(Pritchard & Kola, 1999), point to faulty transcriptional regulation of POLB.  The extra 
chromosome does lead to overexpression of many HSA21 genes (Aït Yahya-Graison et al., 
2007). HSA21 also contains 14 microRNAs: hsa-miR-99a, let-7c, miR-125b, miR-155, miR-802, 
miR-3197, miR-3648, miR-3687, miR-4327, miR-4759, miR-4760, miR-3118-5, miR-3156-3 
and miR-548x (Kozomara & Griffiths-Jones, 2011). MicroRNAs (miRNA) are single strand 
RNA molecules composed of about 19-24 nucleotides (Bartel, 2004) that  repress translation of 
its target genes via binding sites on 3’untranslated regions of mRNA targets.  Studies have 
shown that  5 of 14 HSA21  miRNAs ( hsa-miR-99a, let-7c, miR-125b-2, miR-155 and miR-
802)  play a significant role in the variable phenotypes of DS (Elton, Sansom, & Martin, 2010). 
Studies of miRNA expression, using microarrays and quantitative PCR (qPCR), revealed that 
these 5 miRNAs are overexpressed in DS. Sethupathy et al evaluated expression in fibroblasts 
collected from monozygotic twins, where trisomy penetrance varied and one twin had no 
aneuploidy in skin. DS twin exhibited a 2-fold increase in miR-155 expression compared to 
nonDS twin (Sethupathy et al., 2007). miR-155  and miR-802 were also found to be 
overexpressed in  DS fetal brain and heart tissues, as well as in the hippocampus and whole 
blood of the DS mouse model, Ts65Dn(Keck-Wherley et al., 2011; Kuhn et al., 2008).  
miR-155 is one of the five miRNAs with the potential to regulate POLB and BER. miR-
155 is a multifaceted  microRNA with numerous target genes ((Faraoni, Antonetti, Cardone, & 
Bonmassar, 2009)). It has been implicated in inflammation, cancer, hematopoiesis, immunity and 
DNA repair (Faraoni et al., 2009; Hefti et al., 2016; Keck-Wherley et al., 2011; Khamaneh, 
Alipour, Sheikhzadeh Hesari, & Ghadiri Soufi, 2015; Lashine, Salah, Aboelenein, & Abdelaziz, 
2015; S. Liu, Yang, & Wu, 2011; Teng et al., 2008; N. Valeri et al., 2010; Velazquez et al., 
2016; Yan et al., 2016). Validation studies reveal overexpression of miR-155 eads to  
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downregulation of genes like AID, CEBPB, Ets-1, SHIP-1, FOXO3a, MLH1 and 
CREB1(Faraoni et al., 2009; Hefti et al., 2016; Keck-Wherley et al., 2011; Khamaneh et al., 
2015; S. Kim et al., 2016; Kuhn et al., 2008; Lashine et al., 2015; S. Liu et al., 
2011).Transcription factor CREB1, activator of POLB, was shown to be regulated by miR-155 
(Elton et al., 2010; Lashine et al., 2015; S. Liu et al., 2011).  Overexpression or miR-155 causes 
a decrease in protein levels of CREB1, as well as its targets (Lashine et al., 2015; S. Liu et al., 
2011). POLB promoter studies demonstrated that when levels of CREB1 are compromised, 
POLB levels are also affected (K. H. Chen et al., 1998; Narayan et al., 1994; Pei et al., 2011; 
Podlutsky, Dianova, Podust, Bohr, & Dianov, 2001; Sobol et al., 1996; Srivastava et al., 1998). 
The question becomes, does miR-155 overexpression in DS cause a down regulation of POLB 
and does this play a role in the accelerated aging phenotype of DS? 
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Figure 1.1: Nondisjunction. Failure of the maternal chromosome to separate during meiosis 
causing a zygote with an extra chromosome to be fertilized and Trisomy21 to arise (" National 
Down Syndrome Society," 2012). 
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1 Increased frequency of non-constitutional aberrations 
2 Increased susceptibility to certain types of neoplasm  
3 Premature greying or loss of hair  
4 Dementia or degenerative neuropathology related to senile changes  
5 Increased amyloid deposition  
6 Increased lipofuscin pigments  
7 Diabetes mellitus  
8 Disordered lipid metabolism  
9 Hypogonadism  
10 Autoimmunity  
11 Hypertension  
12 Degenerative vascular disease  
13 Osteoporosis  
14 Cataracts  
15 Mitochondrial abnormalities  
16 Regional fibrosis  
17 Abnormal amounts/distribution of adipose tissue  
 
Table1.2: Pathophysiological and cellular criteria of ageing, adapted from G. M. Martin (1977) 
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Table 1.3: Genes on chromosome 21 implicated in oxygen metabolism(Patterson & Cabelof, 
2012) 
Gene Name 
ATP synthase F0 coupling factor 
NF-E2 related factor (NRF2) (GABPA) 
Amyloid precursor protein (APP) 
Bach1-repressor of oxidative stress response 
TIAM1 
Cytosolic superoxide dismutase (SOD1) 
NADPH: quinine reductase-like (CRYZL1 or NORL1) 
ATP synthase OSCP subunit 
RCAN1 (DSCR1) 
Carbonyl reductase 1 (CBR1) 
Carbonyl reductase 3 (CBR3) 
DYRK1A 
Thioredoxin-like protein (SH3BGR)    
Mitochondrial NADH: Oxidoreductase 10kDa subunit (NDUFV3) 
MIR155HG 
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Figure 1.4: Base Excision Repair pathway  
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CHAPTER 2: LOSS OF DNA POLYMERASEΒ INDUCES SENESCENCE: 
IMPLICATIONS IN DOWN SYNDROME 
 
SUMMARY 
Individuals with Down syndrome exhibit accelerated aging and premature cellular 
senescence.  Correlative evidence for reduced DNA repair capacity, specifically base excision 
repair, is reported in Down syndrome, but no direct connection has emerged. We report here that 
primary fibroblasts from Down syndrome individuals exhibit greater SA-β-Gal staining (20% 
increase, p<0.001) and p16 transcript abundance (3-fold, p<0.01).). We also find that Down 
syndrome fibroblasts senesce more than their diploid counterparts in response to both hydrogen 
peroxide and hydroxyurea. To correlate this increased predisposition to senesce to a specific 
DNA repair deficiency, we measured POLβ transcript levels and find that expression is 
significantly reduced in Down syndrome (~50% decline, p<0.01). To mechanistically connect 
this loss of POLβ to senescence, we assessed polβ-null primary mouse embryonic fibroblasts 
(MEFs) for a senescence phenotype. Here we report that untreated polβ-null MEFs display an 
approximate 2-fold increase in number of senescent cells (p< 0.001) and a 4-fold increase in 
senescent cells in response to hydroxyurea (p<0.05) demonstrating that loss of polβ induces 
senescence. Polβ has not been reported to process DNA damage induced by hydroxyurea. We 
report here an induction in polβ transcript abundance in response to hydroxyurea exposure (2.5-
fold, p<0.01).  Additionally, we report a 5-fold increase in DNA double strand breaks in 
untreated polβ MEFs (p< 0.0001) which is amplified another 2-fold by hydroxyurea (p< 0.001). 
Our findings firmly establish polβ as causative in senescence induction, reasonably establishing 
POLβ and DNA base excision repair as important factors driving aging in Down syndrome. 
 
Introduction 
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A correlation between DNA repair capacity and longevity was first proposed by Hart and 
Setlow (Hart & Setlow, 1974), who correlated mammalian DNA repair capacity to maximum 
lifespan. This association launched an entire field of study into the relative roles of DNA repair 
capacity on lifespan. In turn, many human conditions of premature and/or accelerated aging have 
been directly linked to defective DNA repair (Brosh & Bohr, 2007). Down syndrome is a genetic 
disorder caused by an extra copy of chromosome 21 (trisomy 21), and is characterized by a 
shortened lifespan and biomarkers of precocious aging. The mean life expectancy for individuals 
with Down syndrome has improved greatly from the mid-teens in 1940s (Penrose, 1949) to 
nearly 60 today (Bittles & Glasson, 2004). In addition to shorter lifespan, individuals with Down 
syndrome exhibit signs of accelerated aging. Early onset of Alzheimer’s disease is highly 
penetrant in Down syndrome (Powers et al., 2015). Earlier skin changes, hair changes, 
menopause, vision and hearing impairment, thyroid dysfunction, and immune dysfunction 
(Esbensen, 2010; Hermon et al., 2001; Hill et al., 2003) as well. While other disorders of 
accelerated aging have been connected to specific DNA repair defects, Down syndrome has not.  
As a polygenic condition, the ability to identify a specific gene or pathway responsible for aging 
in Down syndrome is difficult, but there is evidence for reduced DNA repair in Down syndrome 
including: accumulation of DNA repair intermediates in the form of strand breaks (Athanasiou et 
al., 1980; Maluf & Erdtmann, 2001), increased chromosomal damage (Caria et al., 2001; Shafik 
et al., 1988), reduced in vitro measures of repair capacity (S. S. Agarwal et al., 1970; Raji, 
Surekha, & Rao, 1998), and reduced expression of DNA base excision repair genes in human 
Down syndrome samples (Cabelof et al., 2009; Raji et al., 1998).   
 Segal and McCoy first observed that fibroblasts from Down syndrome donors exhibited 
slower doubling time and had characteristics of fibroblasts from old, healthy donors (Segal & 
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McCoy, 1974). Over the years, evidence accumulated that the proliferative potential of 
fibroblasts and lymphocytes from individuals with Down syndrome is reduced (de Arruda 
Cardoso Smith et al., 2004). When cultured, they exhibit many of the features of premature 
aging, such as enlarged and flattened morphology, increased number of multinucleated cells and 
early appearance of SA-β-gal activity (Cristofalo, Lorenzini, Allen, Torres, & Tresini, 2004; 
Kalanj-Bognar, Rundek, Furac, Demarin, & Cosovic, 2002). In fibroblasts isolated from a mouse 
model of Down syndrome, TS65Dn, there is increased SA-β-gal activity and reduced 
proliferation, also seen in skin from these TS65Dn mice (Contestabile et al., 2009). Like 
Cockayne and Werner syndromes, the Down syndrome aging phenotype is characterized by 
subtle reductions in both lifespan and doubling time (Weirich-Schwaiger et al., 1994). In a 
longitudinal evaluation of biological aging in Down syndrome, the estimated rate of aging was 
found to be two-fold greater in Down syndrome (Nakamura & Tanaka, 1998). The impact of 
Down syndrome on aging has also been confirmed at the epigenetic level (Horvath et al., 2015).  
This premature aging has been attributed to the high levels of constitutive, endogenous oxidative 
stress in Down syndrome. 
 The DNA repair pathway primarily responsible for processing oxidative DNA damage is 
the base excision repair (BER) pathway. We have demonstrated inducibility of BER and DNA 
polymeraseβ (POLβ) in response to oxidative stress (Cabelof, 2007; Cabelof et al., 2003; 
Cabelof et al., 2002). Accordingly, we should anticipate an adaptive upregulation in POLβ in 
response to the constitutive oxidative stress of Down syndrome, but this does not occur. Lack of 
an adaptive DNA repair response over the lifespan of the individual with Down syndrome could 
conceivably contribute to a stress induced senescence. Our objective in this work is to establish 
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direct evidence that loss of POLβ drives premature cellular senescence and can mechanistically 
explain the accelerated aging phenotype of Down syndrome.  
Methods and Materials 
Tissue Culture.  Down syndrome (DS) primary fibroblasts (AG06872, AG05397) and their age- 
and sex-matched controls (GM00969, GM05659) were acquired from Coriell Cell Repositories. 
Results are pooled from both cell lines where stated. Cells were maintained in MEM medium 
(Life Technologies, Cat#10370-021) supplemented with 15% fetal bovine serum (Hyclone, Cat# 
SH3007003) and 1% penicillin/streptomycin (Gibco, Cat# 15240-062). DNA polymeraseβ 
(Polβ) null cells, a generous gift from Samuel H. Wilson, were maintained in DMEM (Gibco, 
Cat# 11995081) supplemented with 10% FBS. Polβ-null cells were derived from embryonic 
tissue of homozygous Polβ knockout mice (Sobol et al., 1996). Isogenic MEF cell lines, 
provided by Andrew Jackson, were cultured in DMEM (Gibco, Cat# 11995081) supplemented 
with 10% FBS and 0.1 mM β-mercaptoethanol. All cells were maintained in a 5% CO2 and 3% 
O2 humidified incubator at 37°C. 
SA-β-gal:  Senescence-associate β-galactosidase activity was assessed by using a senescence 
detection kit from BioVision (Milpitas, CA), according to the manufacturer’s instructions. 
Briefly, cells seeded at 5 × 10
4
density were treated for 10-14 days with either hydroxyurea (HU) 
or hydrogen peroxide (H2O2). Cells were fixed for 5 minutes at room temperature and incubated 
with staining solution containing X-gal and staining supplement, overnight at 37°C at ambient 
CO2. Blue-stained cells were identified as senescent. A minimum of 300 cells in at least 5 fields 
of view were photographed and counted at 20X magnification, by two blinded counters. Data 
shown here represent the average of three independent experiments. Results are expressed as 
percentage of stained cells in the total number of cells.  Cells cultured and treated concomitantly 
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with those used to assess senescence were passaged for additional 2 weeks to evaluate their 
ability to recover/emerge from senescence. 
Immunofluorescence staining: 4 × 10
4 
cells were seeded on coverslips in 12-well plates and 
fixed in ethyl: acetate (80:20) for 5 min. After three washes, cells were blocked in PBST 
containing 1% BSA for 30 min at room temperature and incubated with primary anti-H2AX 
antibody (Millipore, Cat# 05-636) for 1.5 hr at room temperature or overnight at 4°C. Cells were 
then incubated with Alexa Fluor 488-conjugated anti-mouse IgG (1:400) (Invitrogen, Cat# A-
11001) for 1 hr at room temperature and mounted with Pro-Long Gold anti-fade reagent 
(Invitrogen, CA). Slides were photographed under the Nikon Eclipse 80i microscope (Nikon, 
CA) and processed using the Nikon Elements built-in software. Approximately 300 cells were 
counted in more than 10 fields of view and those cells displaying more than 7 distinct foci/ 
nucleus were considered positive for -H2AX. 
Expression analysis: cDNA was synthesized, as described previously (Cabelof et al. 2006a), 
from 2µg RNA using random hexamer primers and purified with the QIAquick PCR Purification 
columns (Qiagen, Valencia, CA). Transcripts were amplified and quantitated with a LightCycler 
Real Time PCR machine (Roche). PCR reactions contained 2µl purified cDNA, 0.5 µM of each 
sense and antisense primer, and 2µl FastStart DNA Master SYBR Green I enzyme-SYBR 
reaction mix (Roche). For all amplifications, PCR conditions consisted of an initial denaturation 
step at 95°C for 5 min, followed by 40–45 cycles at 95°C for 10s, primer specific annealing 
temperatures for 10s, and elongation at 72°C for 10s. Melting curves from 65°C to 95°C 
confirmed specificity. External standards were prepared for all genes from cDNA amplicons 
cloned into pCRII TOPO cloning vector (Invitrogen, Carlsbad, CA). All transcripts were 
quantitated and normalized to GAPDH or Rpl4expression where stated.  Primer sequences are 
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detailed in Table 1, with the exception of primer sets used for amplification of human POLβ and 
human p16, which were purchased from SA Biosciences (Frederick, MD) (Cat#PPH13735F-200 
and Cat#PPH00207C, respectively).  
Data Analysis 
Results are expressed as mean ± SEM and were analyzed using Student’s t-test. Statistical 
comparisons between groups were conducted using one-way ANOVA, using GraphPad Prism 
5.0 (Graph Pad Software, La Jolla, CA). Values of p < 0.05 were considered statistically 
significant and individual p-values are shown in the figures. 
Results 
Primary fibroblasts from Down syndrome donors recapitulate the gene dosage phenotype 
of Down syndrome.  
To determine whether primary Down syndrome (DS) fibroblasts recapitulate the gene 
dosage effect of trisomy 21, we evaluated expression of three genes located on chromosome 21 
in cells from age, sex, and race matched individuals without Down syndrome (NDS) and with 
Down syndrome (DS). All three genes are involved in oxidative stress responses: Superoxide 
dismutase 1 (SOD1), Cystathionine-β-synthase (CBS), and BACH1. While not all triplicated 
genes in Down syndrome demonstrate gene dosage effects, SOD1, CBS and BACH1 do. SOD1 
overexpression has been verified in human tissues and DS cell lines (Aït Yahya-Graison et al., 
2007). CBS is involved in the conversion of homocysteine to cystathionine and its upregulation 
in Down syndrome is responsible for the low plasma levels of homocysteine (Perrone et al., 
2007; Pogribna et al., 2001). BACH1 is a transcription factor upregulated in Down syndrome 
(Domenico et al., 2015) that modulates oxidative stress-induced cellular senescence (Dohi et al., 
2008). In Figure 2.1 we show upregulation of SOD1 (5-fold, p<0.01), CBS (>5-fold, p < 0.001), 
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and BACH1 (2-fold, p<0.001) in our Down syndrome fibroblasts, confirming the gene dosage 
effect of trisomy 21. 
Premature cellular senescence in Down syndrome fibroblasts 
Senescence is an irreversible cell cycle state that can be induced by multiple endogenous 
and exogenous signals. Widely used biomarkers of senescence are senescence-associated beta-
galactosidase (SA-β-gal) and p16 expression (Alcorta et al., 1996). SA-β-gal is expressed only in 
senescent cells and is not observed in pre-senescent, quiescent, or transformed cells (Dimri et al., 
1995). Elevated expression of p16 maintains the senescence phenotype and is an established 
marker of premature aging (Alcorta et al., 1996). Further, removal of p16 from senescing tissues 
can reverse senescent phenotypes (Baker et al., 2011).  
Cells were stained for SA-β-Gal and the percentage of X-Gal-positive cells was 
calculated for each cell line. In the absence of exogenous stressors, 5% of NDS fibroblasts stain 
positive while 20% of DS fibroblasts stain positive for senescence (Figure 2.2A, 4-fold increase, 
p<0.001). These data are consistent with previous reports that Down syndrome fibroblasts are 
prone to early cellular senescence (Kalanj-Bognar et al., 2002). In parallel to SA-β-Gal detection, 
we evaluated p16 expression as a function of genotype and find a significant increase in p16 in 
primary DS fibroblasts (Figure 2.2A, 3-fold, p<0.01). When exposed to hydrogen peroxide 
(10uM H2O2), we observe 10% senescent cells in NDS fibroblasts and 35% senescent cells in the 
DS fibroblasts (Figure 2B, 3.5-fold increase p< 0.05). In response to hydroxyurea (HU), we 
observe 21.4% of NDS fibroblasts are senescent while 58.2% of the DS fibroblasts are senescent 
(Figure 2.2B, >2-fold, p<0.01). All SA-β-Gal data were collected 48 h after recovery from the 
final exposure. Cells grown and treated in parallel were maintained in culture for an additional 
two weeks, but never reentered the cell cycle.  
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Reduced DNA polymerase β (POLB) expression in Down syndrome fibroblasts 
As described above, loss of DNA repair capacity, in particular loss of POLβ, has been 
observed in several model systems of Down syndrome. To evaluate a possible DNA repair defect 
in our model system, we examined POLβ expression in two primary fibroblast cell lines from 
each genotype, and find a significant reduction in POLβ expression in Down syndrome (Figure 
2.3, 2.9-fold, ±SEM, p<0.01). This reduction is similar to levels previously reported in the Polβ+/- 
mouse which has been shown to be sufficient to induce a moderate increase in the rate of aging 
(Cabelof, Ikeno, et al., 2006). However, no study of POLβ has yet evaluated a direct role for this 
gene in premature senescence.   
Homozygous loss of DNA polymeraseβ induces premature cellular senescence  
To elucidate a possible role for POLβ in cellular senescence, we evaluated Polβ-/- primary 
mouse embryonic fibroblasts gifted by Samuel H. Wilson (Sobol et al., 1996) for biomarkers of 
senescence, at baseline and in response to exogenous DNA damage. We anticipated a reduced 
DNA damage threshold in response to senescence-inducing agents in the absence of Polβ, but 
were surprised to see a large number of SA-β-gal positive cells in untreated Polβ-/- cells (Figure 
4A, > 11-fold, p< 0.001). p16 was also significantly upregulated in the absence of Polβ, further 
confirming the premature senescence induced by Polβ deficiency (Figure 2.4A, 1.69-fold, 
p<0.001). This is the first direct evidence that Polβ loss is sufficient to induce premature cellular 
senescence. In addition, treatment of Polβ null cells with hydroxyurea resulted in a greater 
increase in both SA-β-gal positive cells (Figure 2.44B, >2-fold, p<0.05) and p16 expression 
(Figure 4B, > 3.5 fold, p<0.001). These data demonstrate both a senescence phenotype induced 
by the absence of Polβ alone and an increased susceptibility to toxic exposures that could further 
contribute to accelerated aging when polβ is inhibited.  
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DNA polymeraseβ protects cells from hydroxyurea-induced DNA double strand breaks. 
This sensitivity of Polβ null cells to HU suggests a role for this gene product in the 
processing of damage induced by HU. To investigate, we evaluated the impact of HU on Polβ 
expression in two isogenic MEF cell lines and found a significant increase in Polβ (Figure 2.5A, 
2.5-fold, p<0.01). Hydroxyurea inhibits ribonucleotide reductase, which alters dNTP/NTP ratios. 
This imbalance generates strand breaks and stalled  replication forks, both known drivers of 
senescence (Yeo et al., 2000). As such, we investigated the impact of HU on DNA double strand 
break (DSB) formation, both in the presence and absence of Polβ.  In wildtype cells, 20% of cells 
contain DSB when exposed to 300uM HU, while in the Polβ null cells this same exposure results 
in over 50% of cells with DSB (Figure 2.5B, >2.5-fold ,  p<0.001). This provides an explanation 
for the increased sensitivity and accelerated senescence of Polβ null cells in response to HU.  
Perhaps more notable is the significant induction of DSB in untreated Polβ null cells.  While 
fewer than 5% of wildtype cells show distinct foci, over 20% of polβ null cells contain DSB 
(Figure 2.5B, 4-fold, p<0.0001). Although loss of Polβ is known to induce DSB and drive 
recombination in response to DNA damaging agents (Horton et al., 2002), this is the first report 
that these breaks arise spontaneously. These data point to a mechanism by which loss of Polβ 
both induces senescence and reduces the threshold of damage able to induce senescence. 
Discussion 
We show here that loss of Polβ is sufficient to induce senescence, both in response to 
accumulating endogenous DNA damage and in response to hydroxyurea exposure, likely by 
reducing the DNA damage threshold for senescence. The offending DNA damage is most likely 
to be DNA double strand breaks (DSB), as hydroxyurea is known to induce senescence through a 
strand break-mediated mechanism (Yeo et al., 2000). The 10-fold increase in level of DSB in the 
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Polβ null cells supports this (Figure 2.5B).  Polβ performs both the DNA synthesis and dRPlyase 
steps of base excision repair (Sobol et al., 1996). In the absence of either enzymatic activity, 
DNA repair intermediates in the form of strand breaks accumulate, as evidenced by 
accumulation of DSB in Polβ-/- cells exposed to methylmethane sulfonate (MMS) (Pascucci et 
al., 2005).  Our finding that DSB accumulate in unexposed Polβ-/- null cells (Figure 2.5B) is the 
first report that loss of base excision repair results in spontaneous DSB.   
Down syndrome presents an accelerated aging model in which there is both increased 
endogenous damage, and reduced DNA base excision repair capacity, a perfect recipe for early 
senescence.  The level of oxidative stress in Down syndrome is constitutively high, and begins in 
utero (Cabelof et al., 2009; Domenico et al., 2015; Nizetic & Groet, 2012; Pogribna et al., 2001).  
The high level of oxidation likely results from the presence of over twenty genes involved in 
oxidative metabolism located on Chromosome 21 (Patterson & Cabelof, 2012). Likewise, the 
base excision repair defect also begins in utero (Cabelof et al., 2009). Under typical conditions, 
both base excision repair and POLβ are induced in response to oxidative stress.  The lack of this 
adaptive response provides a plausible explanation for the early senescence in Down syndrome.   
Base excision repair capacity and Polβ abundance decline by approximately 50% with 
age (Cabelof et al., 2003). Further, the polβ heterozygous mouse expresses 50% less Polβ and 
ages at a slightly faster rate than its wildtype littermates (Cabelof, Ikeno, et al., 2006)). This is 
coincident with an approximate 50% decline in POLβ levels observed in Down syndrome (Raji 
et al., 1998). Thus, POLβ haploinsufficiency in Down syndrome is sufficient to induce aging and 
premature senescence. The question becomes why POLβ is reduced in Down syndrome, and why 
tissues and cells from individuals with Down syndrome fail to respond properly to DNA damage.  
The combination of increased, chronic levels of oxidative stress and reduced DNA repair likely 
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make individuals uniquely susceptible to environmental exposures. In support, children with 
Down syndrome who develop AMkL are highly responsive to chemotherapy (Taub et al., 2000). 
While increased cytotoxicity is desirable in the treatment of pediatric leukemias, it is hazardous 
with respect to unintended enviornmental exposures. With a reduced threshold to senescence, the 
aging observed in Down syndrome may be the result of unknown gene/environment interactions 
in this population. With the incidence of Down syndrome at 14.47 per 10,000 live births (S. E. 
Parker et al., 2010)that is increasing an average of 0.9% per year (Shin et al., 2009), this is a 
highly relevant question and a potentially interesting model for addressing questions pertaining 
to mechanisms of aging as it relates to environmental exposures.   
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TABLES 
 
Gene Sense primer 5′–3′ Anti-sense primer 5′–3' 
Human   
CBS Ggggctgagattgtgaggac cggtactggtctaggatgtga 
SOD1 Ggtgggccaaaggatgaagag ccacaagccaaacgacttcc 
BACH1 Ctcagccttaatgaccagcgg gcctacgattcttgagtggaag 
Mouse   
p16 UPL probe #91 Aatctccgcgaggaaagc gtctgcagcggactccat 
Polβ (exon 12–13) Agcgagaaggatggaaaggaa cgtgcgctctcatgttcttat 
Housekeeping genes    
Gapdh Aggtcggtgtgaacggatttg tgtagaccatgtagttgaggtca 
GAPDH aaggtgaaggtcggagtcaac ggggtcattgatggcaacaata 
Rpl4 ccgtcccctcatatcggtgta  gcatagggctgtctgttgttttt 
Rpl4 UPL probe # 75 tggtggttgaagataaggttga ccaagctttgagtttcttgagc 
 
Table 2.1: Quantitative RT-PCR Primer sequences 
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FIGURES  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Primary Down syndrome fibroblasts exhibit gene dosage effects for oxidative 
stress response genes on chromosome 21.Gene expression was evaluated in primary fibroblasts 
from age, sex and raced matched donors either without Down syndrome (NDS, GM00696 and 
GM05659) or with Down syndrome (DS, AG06872 and AG05397). Transcript levels were 
determined by quantitative RT-PCR and normalized to GAPDH. Data are presented as the 
average of pooled samples from each genotype ± SEM. *Values significantly different from 
control (NDS) at p < 0.01.  
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Figure 2.2: Premature cellular senescence in Down syndrome fibroblasts. A. Down 
syndrome fibroblasts exhibit a premature senescence phenotype. Senescence-associated β-
galactosidase (SA-β-Gal) activity and p16 transcript abundance were measured in primary 
fibroblasts from donors either without Down syndrome (NDS, GM05659) or with Down 
syndrome (DS, AG05397) as described in Methods. A minimum of 300 cells was counted in 
random fields by a technician blinded to genotype to quantify the proportion of SA-β-Gal-
positive cells.  Quantification is presented as the average of three independent experiments ± 
SEM and is expressed as a percent of positive cells [(SA-β-Gal-positive cells/total cells)*100]. 
p16 transcript abundance was determined by quantitative RT-PCR and normalized to GAPDH. 
B. Down syndrome fibroblasts exhibit an amplified senescence response to hydrogen peroxide 
and hydroxyurea. Cells were seeded 24 hours prior to treatment with 10 µM H2O2 or 300µM 
Hydroxyurea (HU) as described in Methods. Briefly, cells were exposed to H2O2 for two hours 
and allowed to recover for 5 days, and to HU every 2 days over a 14 day period. 300 cells were 
counted in random fields by a technician blinded to both genotype and treatment. Quantification 
is presented as the average of three independent experiments ± SEM and is expressed as a 
percent of positive cells [(SA-β-Gal-positive cells/total cells)*100].  *Values significantly 
different from control at p < 0.01. 
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Figure 2. 3. Primary Down syndrome fibroblasts exhibit reduced DNA polymeraseβ 
transcript abundance. Gene expression was evaluated in primary fibroblasts from age, sex and 
raced matched donors either without Down syndrome (NDS, GM00696 and GM05659) or with 
Down syndrome (DS, AG06872 and AG05397). POLβ transcript levels were determined by 
quantitative RT-PCR and normalized to GAPDH. Data are presented as the average of pooled 
samples from each genotype ± SEM. *Values significantly different from control (NDS) 
at p < 0.01.  
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Figure 2.4: Homozygous loss of DNA polymeraseβ induces premature cellular senescence. 
A. Loss of DNA polymeraseβ is sufficient to induce senescence. Senescence-associated β-
galactosidase (SA-β-Gal) activity and p16 transcript abundance were measured in primary mouse 
embryonic fibroblasts from wildtype or from DNA polymeraseβ null embryos as described in 
Methods. 300 cells were counted in random fields by a technician blinded to genotype to 
quantify the proportion of SA-β-Gal-positive cells. Quantification is presented as the average of 
three independent experiments ± SEM and is expressed as a percent of positive cells [(SA-β-Gal-
positive cells/total cells)*100].  p16 transcript abundance was determined by quantitative RT-
PCR using a probe-based system as described in Methods. B. DNA polymeraseβ null mouse 
embryonic fibroblasts exhibit an amplified senescence response to hydroxyurea. Cells were 
seeded 24 hours prior to treatment with 300µM Hydroxyurea (HU) as described in Methods.  
Briefly, cells were exposed to HU every 2 days over a 14 day period. 300 cells were counted in 
random fields by a technician blinded to both genotype and treatment. Quantification is 
presented as the average of three independent experiments ± SEM and is expressed as a percent 
of positive cells [(SA-β-Gal-positive cells/total cells)*100]. p16 transcript abundance was 
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determined by quantitative RT-PCR using a probe-based system as described in Methods. 
*Values significantly different from control at p < 0.01. 
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Figure 2.5: DNA polymeraseβ protects cells from hydroxyurea-induced DNA double strand 
breaks. A. DNA polymeraseβ is upregulated in response to hydroxyurea.  Polβ transcript 
abundance was determined by quantitative RT-PCR in two isogenic MEF lines following HU 
exposure. Expression was normalized to Rpl4, and data is presented as mean ± SEM. *Value 
significantly different from control at p < 0.01.  B. Loss of DNA polymeraseβ induces DNA 
double strand breaks.  DNA double strand breaks were detected by γ-H2AX immunostaining in 
primary mouse embryonic fibroblasts from wildtype or from DNA polymeraseβ null embryos as 
described in Methods. Cells were either untreated or were treated with 300uM HU for 24 hrs, 
fixed and stained with DAPI (blue). Cells were probed with antibody against γ-H2AX (green; 
anti-γ H2AX antibody (Millipore, Cat# 05-636)). A total of ≥300 cells in > 10 fields were 
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counted. Cells were considered positive for double strand breaks if >7 foci per nucleus were 
positive. Data are presented as mean ±SEM. *Values significantly different from control 
at p < 0.01. 
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CHAPTER 3: REGULATION OF DNA POLYMERASEΒ BY MIR-155 
Summary 
 
In this chapter we elucidate the link between Polβ downregulation and Down syndrome 
genotype. DS, unlike other premature aging syndromes, provides a non-monogenic model to 
study the effects of trisomy 21 on aging and DNA repair. Here, we set out to determine whether 
HSA21-localized miR-155 played any role in regulating Polβ. Although Polβ does not have a 
miR-155 seed on its 3’UTR, there is ample evidence that Creb1, a transcriptional regulator of 
Polβ, is a direct target of miR-155. miR-155 overexpression causes a reduction in Polβ promoter 
activity, as well as a decrease of both Creb1 and Polβ protein levels.  Data from proteomics study 
reveals that other BER genes are also differentially affected by miR-155 overexpression. Further 
investigation into the precise mechanisms of Polβ inhibition by miR-155 is necessary in order 
understand the effects of Trisomy 21 on DNA repair.      
          
          
         
         
          
        
       
 
Figure 3.1: Proposed mechanism of miR-155 regulation. 
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3.1 Introduction 
Down syndrome is a genetic disorder characterized by an accelerated aging, as result of 
increased genomic instability. This is due to an imbalance between increased DNA damage and 
decreased repair.  Individuals with DS have high constitutive oxidative stress linked to the 
overexpression of HSA21 genes SOD1, APP1, and BACH1 (Domenico et al., 2015; El-
Bassyouni et al., 2015; Nizetic & Groet, 2012; Patterson & Cabelof, 2012; Rodriguez-Sureda et 
al., 2015; N. Rueda et al., 2012). Typically, damage induced by oxidative stress is repaired by 
base excision repair (BER), a process in which POLB is the rate limiting enzyme. We have 
established that DS and Polβ null fibroblast exhibit high levels of senescence markers: SA beta 
gal staining and p16 expression. DS fibroblasts show a reduced POLβ expression that correlates 
with increase in senescence.  Data from Polβ nulls cells confirm that Polβ loss alone is sufficient 
to induce senescence.   
In this study, we explore the underlying mechanism responsible for the negative 
regulation of Polβ. Non-protein coding RNAs have recently been shown to play an important 
role in regulating multiple DNA repair pathways. The 20-nucleotide long miRNAs bind to 
specific 3’-UTR sites on target RNAs and limit the activity of targeted proteins, by either 
inhibiting translation or degrading the transcript.  It is estimated that miRNAs regulate 
approximately 30% of protein-coding genes (Bartel, 2004).  
Five miRNAs are found on chromosome 21: miR-99a, let-7c, miR-125b2, miR-155 and 
miR-802. miR-155 is overexpressed in the fetal brain, fetal heart, and fibroblasts of DS 
individuals  (Hefti et al., 2016; Sethupathy et al., 2007), as well as in the hippocampus and whole 
blood of the Ts65DN mouse (Keck-Wherley et al., 2011). miR-155 has been shown to negatively 
regulate DNA mismatch repair (MMR)(Nicola Valeri et al., 2010). It does so by binding to 
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mismatch repair genes, hMSH2, hMSH6, and MLH1, causing their downregulation.  This results 
in impaired MMR (N. Valeri et al., 2010). MiR-155 also affects DSB repair, by inhibiting Rad51 
(Gasparini et al., 2014), a gene responsible for strand invasion during homologous recombination 
(HR). A recent study showed that miR-155 is also involved in non-homologous end-joining 
(NHEJ), via transcription factor FOXO3a (Czochor, Sulkowski, & Glazer, 2016), which 
modulates DNA repair through Gadd45a and PCNA. This paper also demonstrated that miR-155 
overexpression results in significant reduction in DNA polymerase delta (POLD) (Czochor et al., 
2016). 
MiR-155 could potentially regulate BER, via translational inhibition of transcription 
factor Creb1. Creb1 has 3 putative binding sites for miR-155 on its 3’-UTR and has been shown 
to be negatively regulated by miR-155 (Y. Chen et al., 2013; Gaudet et al., 2016; Lashine et al., 
2015; S. Liu et al., 2011).  miR-155 overexpression causes decreased levels of CREB1 and its 
targets (Lashine et al., 2015; S. Liu et al., 2011), while miR-155 knockout results in restored 
Creb1 (Gaudet et al., 2016).  BER activity is dependent on Creb1 binding to the c-AMP-response 
element (CRE) site at positions -49 to -40 in the mouse Polβ promoter (Kedar et al., 1991; 
Narayan et al., 1994; Sobol et al., 1996; Widen & Wilson, 1991). Promoter studies from Wilson 
group have clearly demonstrated that Creb1 binding to the Polβ promoter is crucial for Polβ 
transcription and efficient BER activity (Srivastava et al., 1998) A zebrafish study also showed 
that reduced Creb1 in Ape1 knockdown results in low Polβ expression (Pei et al., 2011), a 
finding we have also seen in brain and liver of Ape1 heterozygous mice (Raffoul et al., 2004).  
Thus, we sought to establish whether miR-155 overexpression, characteristic of the 
overexpression seen in DS, could explain the low Polβ levels observed in these individuals. 
 
42 
 
 
3.2 Materials and Methods 
Tissue Culture SV-40 transformed mouse embryonic fibroblasts (MEFs; Tag 92), a generous 
gift from Robert W. Sobol, were maintained in DMEM (Gibco, Cat# 11995081) supplemented 
with 10% FBS, in a 5% CO2 and 20% O2 humidified incubator, at 37°C.   
Transfections  SV40 transformed mouse embryonic fibroblasts (MEFs) were electroporated 
with either pEGP-miR-155 or pEGP-miR-null. Cells incorporating the construct were selected 
and pooled by treatment with puromycin. Briefly, cells were grown to 75% confluence, then 
collected and counted. 1x10
6
 cells in 200 ul volume were transferred into a sterile Bio-Rad 
GenePulser electroporation cuvette (0.2 cm; Bio-Rad) along with 10 μg of pEGP-miR-155 or 
control pEGP-miR-null (Cell Biolabs, San Diego, CA) plasmid DNA. The mixture was gently 
mixed, then pulsed at 220 V and 500 μFD,  using a Bio-Rad GenePulser electroporation 
apparatus (Bio-Rad). Freshly electroporated cells were then transferred into 6–well plates 
containing 2ml of complete growth media and incubated at 37°C and 5% CO
2
 for 24 hours.  The 
media was changed after 24 h and total RNA was extracted using Trizol (Invitrogen) at 72h 
posttransfection. Stable clones were selected beginning at 48h posttransfection  with 3μg/ml 
puromycin (Sigma-Aldrich, St. Louis, MO), for 2 weeks.  
Plasmid constructs  A plasmid containing the Polb core promoter (positions -114 to +62), 
which exhibits the same CAT activity as a 4.6kb fragment, was kindly gifted by Dr. Samuel 
Wilson. The promoter sequence was PCR-amplified using the following primers: forward 
5’CCGCGCCGGCACGCCTCACAAACAGTA-3’and reverse 5’GAGCCGGAGGGCGGCCC 
GGGACTCAC-3’. Subsequently, it was cloned into the pGL3 basic vector, upstream of the 
luciferase gene. The CRE site in the minimal promoter was mutated  
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(TGACGTCA TGAatTC) by using the Q5 Site-Directed Mutagenesis kit (NEB, Ipswich, MA) 
with the following primers: forward TGGCGCGTGAATTCACCGCGCTGCGCC and reverse 
GGCTACGGGGCGGGGCTA.  Both constructs were sequenced to verify accuracy. 
MicroRNA 155 Expression Total RNAs was isolated using Trizol.  50 ng of total RNA were 
used for reverse transcription (RT). RT reactions comprised  0.15 μL dNTP, 1.5 μL buffer (10x), 
9 μLRNAse-free water, 0.2 μLRNAse inhibitor, 1 μL Multiscribe Reverse Transcriptase, and 3 
μL of specific miR-155  RT primers (Applied Biosystems). RT reactions for primer extension 
and synthesis of the first cDNA strand were set at 16°C for 30 minutes, 42°C for 30 minutes, and 
85°C for 5 minute, using a BioRad thermal cycler. The TaqMan miR-155 assay (Applied 
Biosystems) was used to quantify miR-155. 5 μL of RT reaction were mixed with 10 μL of 
TaqMan Universal PCR master mix (Applied Biosystems), 4 μL of RNAse-free water, and 1 μL 
of TaqMan miRNA Assay (Applied Biosystems). Quantitative real-time PCR analysis was 
performed using LightCycler 480 (Roche) at 95°C for 10 minutes, followed by 40 cycles of 95°C 
for 15 seconds, and 60°C for 60 seconds.  Sno202 (Applied Biosystems), a noncoding RNA, was 
used as endogenous control. 
Expression analysis cDNA was synthesized, as described previously (Cabelof et al. 2006a), 
from 2µg RNA, using random hexamer primers and purified with the QIAquick PCR 
Purification columns (Qiagen, Valencia, CA). Transcripts were amplified and quantitated with a 
LightCyclerReal Time PCR machine (Roche). PCR reactions contained 2µl purified cDNA, 0.5 
µM of each sense and antisense primer, and 2µl FastStart DNA Master SYBR Green I enzyme-
SYBR reaction mix (Roche). For all amplifications, PCR conditions consisted of an initial 
denaturation step at 99°C for 10 min, followed by 35–45 cycles at 96°C for 10s, primer specific 
annealing temperatures for 10s, and elongation at 72°C for 5s. Melting curves from 40°C to 99°C 
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confirmed specificity. External standards were prepared for all genes from cDNAamplicons 
cloned into pCRII TOPO cloning vector (Invitrogen). All transcripts were quantitated and 
normalized to GAPDH or RPL4 expression. Primer sequences are detailed in Table 3.1. 
Western blotting Cells overexpressing miR-155 and null were pelleted and stored at -80°C until 
further use. Nuclear proteins were extracted using the NucBuster™ Protein Extraction Kit 
(Novagen, Darmstadt, Germany) and quantified using the Pierce BCA Protein Assay Kit 
(Thermo Scientific), as per the manufacturer protocols. 40 ug of nuclear extracts were ran on 
10% TGX Stain-free precast gels (BioRad) and transferred to 0.2um PVDF by using the Trans-
Blot Turbo Transfer System (BioRad), according to the manufacturer’s recommendations. 
Loading and transfer consistency was determined by UV-activation of the gel and membrane. 
Following activation, blots were incubated for 30 minutes in blocking buffer (5% BSA in PBST) 
and overnight at 4C in primary antibodies, at 1:500 dilutions: CEBP  (Abcam, ab18336) and 
Pol Abcam, ab3181). Blots were subsequently washed in PBST and incubated for 90min at 
room temperature in anti-mouse IgG-HRP secondary antibody (Cell Signaling, #7076), diluted at 
1:5000 in PBS.  Bands were detected using a ChemiImager, following activation with the 
SuperSignal Chemiluminescent Substrate luminol/enhancer (BioRad). Optical density was 
determined using ImageJ (Schneider, Rasband, & Eliceiri, 2012) and data were expressed as 
band intensity normalized to total protein intensity. 
Luciferase Assay Stable miR-155 and control clones were co-transfected with 5ug of pGL3-
Polβ promoter plasmid, which includes the CRE binding site (TGACGTCA), and 25ng of 
Renilla vector, which acts as control for transfection efficiency. The mixture was gently mixed, 
then pulsed at 200V and 500 μFD, using a Bio-Rad GenePulser electroporation apparatus (Bio-
Rad, Hercules, CA).  Media was changed 24 hours posttransfection and cells were grown for 
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additional 24 hours before analysis. Luminescence was detected using a Dual Luciferase assay 
(Promega, Madison, WI, USA) and quantified with a Turner Biosystems 20/20 Luminometer 
(Promega). Relative light units (RLUs) were calculated as luciferase activity normalized to 
Renilla activity. Data represent the average ± standard deviation of triplicate samples.  
Proteomics  
Stable isotope labeling with amino acids in cell culture  (SILAC): Select miR-155 
overexpressing and null cell lines were  maintained in DMEM media supplemented with 10 % 
dialyzed fetal bovine serum, 0.46 mM l-Lys-HCl or 0.46 mM13C6, 15N2-Lys-HCl, 0.47 mM l-
Arg-HCl or 0.47 mM 13C6-Arg-HCl, 200 mg/L l-proline, 2 mm glutamine, 100 U/mL penicillin, 
and 100 µg/mL streptomycin, in a humidified 5 % CO2 atmosphere (G. C. Parker, Carruthers, 
Gratsch, Caruso, & Stemmer, 2016).  Cells were passaged three times a week and harvested for 
experiments after six passages in the SILAC media. Cells were harvested by washing and 
scraping, then spun and stored in pellets at −80°C until analysis. 
Sample preparation Cells were resuspended in 100 µL of water, followed by addition of 100 µL 
of 2 % LiDS, and incubation in 95 °C water for 5 min. Proteins in the lysates were determined 
using a BCA protein assay (Pierce, Rockford, IL). Equal amounts of protein from SILAC heavy 
and light cell lysates were combined and treated with 10 mM DTT and alkylating agents with 30 
mM iodoacetamide, before adding 10 mM additional DTT. Samples were fractionated on 10 % 
polyacrylamide SDS-PAGE gels and stained with Coomassie blue. Each of the three sample 
lanes was divided into 30 fractions with the edges of each lane removed prior to slicing for 
analysis. Proteins in the gel were digested overnight with 0.04 μg trypsin per slice in buffer 
containing 20 mM Tris (pH 8.0) and 10 % acetonitrile. Eluted peptides solubilized in 0.1 % 
formic acid were analyzed by LC–MS/MS, without further purification. 
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LC-MS/MS analysis Two GelC-30 SILAC experiments were performed:  C1 with miR-155 
heavy and null light and C2 with null heavy and miR-155 light.  Mass spectra were searched 
against the Uniprot mouse database downloaded 2014.06.24, using MaxQuant version 1.5.28.  
Cysteine carbamido methylation was specified as a fixed modification and protein N-terminal 
acetylation and methionine oxidation were specified as variable modifications (Carruthers, 
Parker, Gratsch, Caruso, & Stemmer, 2015).  Unique and razor peptides were both used for 
protein quantification.  We identified 3342 proteins that were present in both SILAC 
experiments. An abundance ratio (miR-155/null) was determined for each protein group using 
ratios from all peptides that could be assigned to it.  Ratios were log-transformed and normalized 
so that the median log-fold change for each experiment was 0.   
Immunofluorescence staining 4 × 10
4 
cells were seeded on coverslips in 12-well plates and 
fixed in ethyl: acetate (80:20) for 5 min. After three washes, cells were blocked in PBST 
containing 3% BSA for 30 min at room temperature and incubated with primary anti-
antibody (Millipore, Cat# 05-636) for 1.5hr at room temperature or overnight at 4°C. Cells were 
then incubated with Alexa Fluor 488-conjugated anti-mouse IgG (1:400) (Invitrogen, Cat# A-
11001) for 1 hr at room temperature, and mounted with Pro-Long Gold anti-fade reagent 
(Invitrogen, CA). Slides were photographed under the Nikon Eclipse 80i microscope (Nikon, 
CA) and processed using the Nikon Elements built-in software. Approximately 300 cells were 
counted in more than 10 fields of view and those cells displaying more than 7 distinct foci/ 
nucleus were considered positive for γ-H2AX. 
Data Analysis 
Results are expressed as mean ± SEM analyzed and were analyzed using Student’s t-test. 
Statistical comparisons between groups were conducted using one-way ANOVA, using 
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GraphPad Prism 5.0 (Graph Pad Software, La Jolla, CA). Values of p < 0.05 were considered 
statistically significant and individual p-values are shown in the figures. 
3.3 Results 
We generated several miR-155-overexpressing clones, exhibiting a range of 2-12 fold 
miR-155 overexpression (Figure 3.3.1a, p<0.05). Most of the subsequent experiments were done 
in clone 3, which overexpresses miR-155 at levels 2-3 fold above control, consistent with the 
level of overexpression observed in DS.  This level of miR-155 overexpression is therefore 
relevant to our objective of studying gene dosage of Trisomy 21. Additionally, we confirmed our 
mir-155 overexpression by quantifying protein levels of previously validated targets of miR-155. 
Cebpβ, previously shown to be negatively regulated by miR-155 (Jiang et al., 2012; S. Kim et 
al., 2016), had reduced protein levels in our engineered miR-155 MEFs (Figure 3.3.1b).   
Next, we analyzed changes in PolβmRNA and protein in two stable miR-155 clones (2 – 
and 12-fold).  The low overexpressing cells showed an approximate 50% reduction in Polb 
transcript (p< 0.01 Figure 3.2a), reflected also by reduced PolB protein. However, cells 
overexpressing miR-155 at ~12 fold showed no difference in Polb transcript and protein, 
suggesting a dose dependent regulation (Figure 3.2b).  
To evaluate the impact of miR-155 overexpresssion on promoter activation, we have 
cloned the PolB core promoter, including the CRE site, into a luciferase vector as described in 
Methods.  We find that overexpression of miR-155 effectively inhibits PolB promoter activity by 
almost 5 fold (Fig 3 p<0.01). In addition, when the Creb1 binding site in the core promoter is 
mutated, the luciferase activity becomes undetectable. Taken together, these in vitro results 
suggest that miR-155 inhibition of Creb1 translation could be responsible for PolB inhibition. 
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We show in Chapter 2 that Polβ null cells exhibit a high number of DSBs, both at 
baseline and in response to DNA damage. A recent study also showed that cells overexpressing 
miR-155 leads to initiation of the error prone NHEJ repair (Czochor et al., 2016).  The 
mutational specificity of miR-155 overexpression is consistent with upregulated NHEJ 
(Czochor…), but not consistent with a MMR deficiency, suggesting that the DNA repair defects 
induced by miR-155 overexpression are related more to strand break resolution and less to post 
replication repair.  To further investigate this point, we measured DSB by γ-H2AX staining in 
miR-155 overexpressing cells. In the miR-155 clone that mimicked DS conditions, we saw an 
almost 17% increase in γ-H2AX foci compared to ~ 4% increase in the null control (Figure 
3.4a). In the miR-155 clone with 12-fold overexpression, we did not see either an increase in 
DSB or a loss of Polβ(Figure 3.4b), strengthening the connections between Polβ loss and DSB 
formation.  Further, this creates an opportunity to connect the mutagenicity and DNA damage of 
miR-155 overexpression to polB and altered BER.  
In order to conduct an unbiased evaluation of the impact of miR-155 overexpression on 
DNA repair genes, we employed an unbiased proteomic approach to discover which DNA repair 
proteins and pathways are affected by miR-155 overexpression. Stable isotope labeling with 
amino acids in cell culture (SILAC) is a tool that allows for differential labeling of amino acids. 
Amino acids with substituted stable isotopic nuclei labeled either “light” or “heavy “are 
introduced into the growth medium. Cells in culture will incorporate the labeled amino acid 
instead of the natural amino acid into all newly synthesized proteins (Mann, 2006).  LC-MS/MS 
allows for analysis of the ratio between light and heavy in each identified peptide.   This 
approach generated 4000 differentially expressed proteins in response to miR-155 
overexpression.  Preliminary analysis of these 4000 proteins revealed the pleiotropic effects 
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known to be exerted by this promiscuous miRNA.  Multiple pathways and numerous gene 
products are differentially impacted by miR-155 overexpression, even at low levels of 
overexpression. Using the beta version of DAVID 2008, we established that these proteins 
belong to these processes such as: oxygen metabolism, dNTP metabolism, DNA damage 
response, and DNA repair. We have validated our proteomics findings both by comparing the 
proteins identified in our screen to those that have been previously validated as direct targets of 
miR-155 (Table 3.5.1), and by western analysis.  Using the DIANA tool in TarBase (Vlachos et 
al., 2015), we set protein identification filters for: mus musculus, directly validated targets of 
miR155, and a prediction score of >0.95.  This generated a list of 31 total mouse proteins 
identified as direct miR-155 targets that have been published in the literature.  Table 3.5.1 lists 
the proteins that overlap with our proteomics data, and 12 of our genes match the list generated 
by DIANA.  39% of all prior validated targets for miR-155 in mus musculus are represented in 
our data set.  This is particularly interesting in light of the fact that our system employed a 
completely different cell type (fibroblasts), pointing to the potential universality of the effect of 
miR-155 on these specific gene products.  In addition, by western analysis we measured protein 
levels of CEBPβ, a known human target of miR-155 (S. Kim et al., 2016), and find that in our 
system we likewise see downregulation of this miR-155 target. 
Next, we evaluated our data set for differential expression of DNA repair proteins.  i We 
find that theMMR proteins MSH6 and MSH2 are reduced in miR-155 overexpressing cells, 
consistent with published reports(N. Valeri et al., 2010).  Interestingly, we found that several 
BER genes downstream of Polβ are also affected (Table 3.5.2).  However, a search using the 
TargetScan database revealed that none of theBER genes contain seed sequence for miR-155 in 
their 3’-UTR, suggesting an indirect regulation by miR-155(V. Agarwal, Bell, Nam, & Bartel, 
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2015). Notably, all the upregulated BER proteins shown in Table 3.5.2 are downstream of the 
PolB reaction in BER.  
3.4 Discussion 
miR-155 is one of the most widely studied microRNAs. Based on its broad importance 
and on its known impact on another DNA repair pathway, mismatch repair, we set out to 
determine whether HSA21-localized miR-155 played any role in regulating Polβ. While there is 
no indication that Polβ would be a direct target of miR-155, there was abundant evidence that the 
transcription factor,Creb1,  was directly, negatively regulated by miR-155 (S. Liu et al., 2011).  
Because Creb1 and the CRE in the Polβ promoter are essential for transactivation of polB 
transcription, we hypothesized that inhibition of Creb1 by miR-155 would negatively impact 
Polβ expression.  Our data clearly establish that miR-155 overexpression results in 
downregulation of Polβ expression. In miR-155 overexpressing MEFs, we show downregulation 
in both Polβ transcript and protein. This is the first reported effect of miR-155 on a DNA repair 
protein outside the MMR pathway, and points to a role for Polβ in the phenotypes induced by 
miR-155 overexpression.  In chapter 2 we demonstrated clearly that loss of Polβ results in a 
significant accumulation of DNA DSB.  Here we find that miR-155 overexpression likewise 
causes accumulation of DSBs, conceptually tying the loss of Polβ in miR-155 overexpressors to 
the DSB. This is interesting and counterintuitive within the context of a recent paper in which 
strand breaks were suppressed in miR-155 overexpressing cells, but were elevated in cells with 
miR-155 silenced (Czochor et al., 2016).  However, in that work the level of miR-155 
overexpression was more than 50-fold overexpression.  In that same paper, the authors found no 
impact of miR-155 on Polβ, but did see a reduction in Polδ.  Our data set, on the other hand, 
showed no effect on Polδ.  Many studies investigating the roles of miRs on various outcomes 
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utilize systems that largely overexpress the miR of interest (hundreds of folds overexpression).  
This may be relevant to the study of cancer, as some types of cancer exhibit large fold increases 
in miR-155 expression.  But for our purposes of studying the impact of a trisomy 21-induced 
gene dosage effect of miR-155, those studies are irrelevant.  One important finding to come from 
our studies is that the level of overexpression can drastically vary the impact of miR-155 on its 
targets, and that blanket statements about the role(s) of this miRNA must take into consideration 
dosage context.   
To extend our investigation into a more complete evaluation of the entire BER pathway, 
we looked in Target Scan for BER(V. Agarwal et al., 2015) genes that might have miR-155 seed 
sequence in their 3’UTR, but found none.   However, this approach does not take into 
consideration potential indirect targets, like in the case of Polβ.  So we proceeded to compare our 
proteomic data set against all known DNA repair proteins (Wood RD, 2014)and found several 
BER proteins downstream of the Polβ step of BER that are also affected by miR-155 
overexpression (Table 3.5.2). Notably, these proteins are all upregulated.  Each of these genes 
conceivably plays a role in helping to resolve the DNA repair intermediates induced by loss of 
Polβ (i.e., DNA single strand breaks).  We suggest that the loss of Polβ generates damage that 
induces an adaptive response in these particular BER genes to minimize the impact of 
accumulating repair intermediates on the formation of DSB.  Because single strand breaks at the 
replication fork can cause replication stress and DSB accumulation, we further suggest that 
eliminating these proteins should amplify the DSB accumulation induced by miR-155 
overexpression.     
To conclude, our data definitively show that miR-155 overexpression inhibits Polβ and 
induces DSB.  It remains unclear what the mechanism of Polβ inhibition may be.  We propose 
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two possible mechanisms.  The first is through Creb1 downregulation induced by miR-155 
overexpression, as described above and supported by the reduced protein levels of Creb1 we 
observe when we overexpress miR-155 (data not shown). Another, not mutually exclusive 
mechanism could be through Foxo3.  miR-155 could regulate BER via FOXO3a and its target, 
Gadd45a. Gadd45a has been shown to activate BER and play a role in recruiting other DNA 
repair genes. As such, inhibition of Gadd45a by Foxo3 could block BER.  Further investigation 
into the precise mechanisms of Polβ inhibition by miR-155 is necessary in order to move toward 
developing interventional strategies to protect genome integrity in individuals with Down 
syndrome.  
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Gene Sense primer 5′–3′ Anti-sense primer 5′–3' 
Mouse   
B-pol (exon 12–13) agcgagaaggatggaaaggaa Cgtgcgctctcatgttcttat 
Housekeeping genes (mouse)   
Gapdh aggtcggtgtgaacggatttg Tgtagaccatgtagttgaggtca 
Rpl4 ccgtcccctcatatcggtgta Gcatagggctgtctgttgttttt 
Rpl4 UPL probe # 75 tggtggttgaagataaggttga Ccaagctttgagtttcttgagc 
 
Table 3.1: Primer sequences 
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Figure 3.2 SILAC-based quantitative proteomics.  Flowchart of double SILAC coupled with 
LC-MS/MS .  
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Figure 3.3.1: Ectopic overexpression of miR-155 in MEFs. miR-155 overexpression in MEFs  
by electroporation  is confirmed by qRT-PCR and normalized  endogenous control, sno202.  
Data presented is average ± SEM. Delta ΔΔ CT method was used to calculate fold change. 
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Figure 3.3.2: Validation of C/EBP β downregulation in miR-155.  The levels of C/EBP β 
protein  from miR-null and miR-155 overexpression cells  was determined by western blot 
analysis. The level of  C/EBP β protein was normalized  to whole protein.  Data are presented as 
means ± SEM of four replicates. 
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Figure 3.3.3: Polβ transcript and protein  expression is downregulated in miR-155 Cells.  
Polβ transcript expression  was determined by q RT-PCR in miR-null and miR-155 
overexpression cells.. Expression was normalized to Rpl4, and data is presented as mean ± SEM. 
*Value significantly different from control at p < 0.01.  The levels of Polβ protein was 
determined by western blot analysis. The level of Polβ protein was normalized to whole protein.  
Data are presented as means ± SEM of three biological replicates. 
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Figure 3.3.4:Polβ  Promoter activity is inhibited by miR-155 overexpression. A. Polβ 
constructs (2 μg) were co-transfected with a Renilla luciferase plasmid, serving as an internal 
control for transfection efficiency, into miR-null and miR-155 cells, and luciferase activity was 
measured 48 h post-transfection. . B. Luciferase expression in Mutated PolB construct 
transfected into miR-null cells.  
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Validated miR-155 targets  up/down cell type(s)  Our data 
fold 
change 
Myo1d Down Muscle Down 2.68 
Nr2f2 Down Muscle Down 1.5 
Strn3 Down Muscle Up 1.41 
Rps6ka3 Down Muscle Down 1.28 
Trps1 Down Muscle Up 1.24 
Rcor1 Down T cells; muscle Up 1.22 
Tab2 Down 
T cells; stem 
cells Down 1.19 
Fosl2 Down T cells; muscle Down 1.18 
Kdm2a Down T cells; muscle Up 1.18 
Irf2bp2 Down T cells; muscle Down 1.1 
Cdc73 Down T cells; muscle Up 1.05 
Pkn2 Down T cells Up 1.03 
     
 
Table 3.3.5 Validated  miR-155 targets shown in our dataset.   
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DNA REPAIR  
Fold 
change 
Mismatch repair 
 MSH3 -1.8 
MSH2 -1.3 
MSH6 -1.3 
BER/strand 
break 
 DNA ligase3 1.31 
DNA ligase 1 1.41 
Xrcc1 1.46 
Pnkp 2.12 
Parp2 1.76 
Fen1 1.26 
Xrcc4 1.37 
DNA polk 1.5 
 
TABLE 3.3.6: Impact of miR-155 overexpression on proteins involved in DNA repair. 
Proteins involved in MMR and BER/SSB 
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CHAPTER 4: TS65DN MOUSE MODEL 
4.1 Summary 
It is important to consider that no mouse model can be a perfect model of DS, for the 
reasons eneumerated below, and as summarized in Vacano et al. (Vacano, Duval, & Patterson, 
2012). That said, the Ts65Dn model phenocopies much of DS, even though it is trisomic for only 
about 50% of the HSA21 genes. This model is particularly appropriate as it exhibits signs of 
premature aging(Adorno et al., 2013):fibroblasts from these mice senesce early (Contestabile et 
al., 2009). Our objective was to do an extensive evaluation of aging and senescence in tissues 
from these mice and their disomic littermates (WT) at different ages. Experiments were 
conducted in male mice only, to preserve female animals for breeding purposes. Expression 
levels of p16 and Polβ will allow us to correlate premature aging and reduced DNA repair 
capacity.  
4.2 Introduction 
Mouse models have been one of the most useful tools in studying DS pathogenesis due to 
the homology existing between human genes on chromosome 21 and mouse genes on 
chromosome 16, chromosome 10 and chromosome 17 (Rachidi & Lopes, 2007).  Mouse models 
allow scientist to dissect many of the features of DS as well as develop therapeutic drugs for 
aliments that afflict individuals with DS. In the last 40 years researchers have been able to study 
the molecular, cellular, physiological, and behavioral phenotypes observed in human DS through 
the use and manipulation of mouse models.   
Two types of mouse models have been developed to study the molecular genetics of DS: 
segmental trisomic models and transgenic models. Each model has its limitation but each offer 
insight into the molecular mechanisms driving the DS phenotype.  The segmental trisomic 
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models have the advantage of mimicking many of the clinical phenotypes observed in DS 
individuals. Despite this, their drawback remains  species-specific gene differences between 
mice and humans (Rachidi & Lopes, 2007). Alternatively, the transgenic mouse models, 
overexpressing only one or few genes, allow a direct genotype–phenotype relationship, but the 
disadvantage of these mouse models is the loss of critical interactions between genes present at 
three copies(Rachidi & Lopes, 2007).   
4.3 Trisomic mice 
The first mouse model of DS developed was Ts16using the rationale that MMU 16 and 
HSA21 were close in sentry.  A breeding scheme using a balanced Robertsonian translocation of 
MMU 16 was devised.  A male mouse carrying Robertsonian translocations of MMU 16 was 
mated with a normal female thus producing approximately one-third of the progeny with 
Trisomy of MMU16. The model presents several characteristics of DS such as increased 
oxidative stress, mitochondrial dysfunction and nervous system impairment (Cox, Smith, 
Epstein, & Epstein, 1984; Pagano & Castello, 2012). Ts16 mice develop cardiovascular 
anomalies similar to those seen in DS (Villar et al., 2005).  Severe thymic hypoplasia and 
delayed maturation of thymic lymphocytes are also observed in Ts16 mouse (Epstein, Cox, & 
Epstein, 1985). The key function of the thymus is to provide an area for T-lymphocyte 
maturation and in DS this process is significantly impaired (Kusters, Verstegen, Gemen, & de 
Vries, 2009; Peled-Kamar et al., 1995) . DS children display many signs of thymic hypoplasia 
such as  T-cell dysfunction and increased risk for infections, lymphoproliferative disorders, and 
autoimmune diseases (De Leon-Luis et al., 2011).   
With respect to cognitive function, Gearhart et al demonstrated impairment in the 
development of the basal forebrain cholinergic neuron (impaired learning) and increased 
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susceptibility of these mice to develop AD.  They exhibit a two fold increase in amyloid 
precursor protein (APP) accumulation, a protein implicated in senile plaque formation in AD.   
Cells cultured from these Ts16 mice have led to substantial insight on neuronal development in 
DS as well as in Alzheimer disease (AD). Ts16 lines overexpress other key genes involved in the 
pathogenesis of AD. These include Cu/Zn superoxide dismutase (SOD-1), Ets-2 transcription 
factors and Down Syndrome Critical Region 1 (DSCR1) stress-inducible factor (Lott, Head, 
Doran, & Busciglio, 2006). The overabundance of these genes due to Trisomy causes a 
pathological cascade that cause oxidative stress and a neurogeneration typical of AD (Lott et al., 
2006).  These findings are analogous to what is observed in DS brain.   
Nonetheless Ts16 is not an ideal model due to its many imperfections vis-à-vis human 
DS.  It does not accurately recapitulate human DS aneuploidy because Mmu16 is bigger than 
HSA21 and contains many genes homologous with HSA3, HSA8, HSA16, and HSA21 (Noemí 
Rueda, Flórez, & Martínez-Cué, 2012).  The extra genes that are not implicated in DS may 
contribute to the perceived DS phenotype in the mouse modes, confounding the story.  Further, 
one key characteristic of DS is degeneration of basal forebrain cholinergic neurons (BFCNs). 
The Ts16 mouse does not exhibit this trait, and many others as well, so it does not faithfully 
recapitulate enough of the DS phenotype to be an ideal model.  Another disadvantage is that the  
Ts16 genotype is embryonic lethal limiting the ability to research postnatal DS phenotypes 
l(Seregaza, Roubertoux, Jamon, & Soumireu-Mourat, 2006; Villar et al., 2005).   
Another model, the Ts(16C-tel)1Cje (Ts1Cje) mouse, is created by  a translocation 
between MMU12 and MMU16.  When a gamete carrying MMU12
, 
with translocation of MMU 
16, and another complete MMU16 combines with a normal gamete, a partial Trisomy of the 
distal region of MMU16 results(Sago et al., 1998) .  Consequently this scheme allows only a 
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small region of MMU16 to be trisomic, and about one third of genes seen in the Ts65Dn model 
are trisomic in Ts1Cje mice (Dierssen et al., 2001).  Unlike Ts65Dn(described below), Ts1Cje 
mice exhibit very few DS phenotypes.  Craniofacial anomalies are not visible, learning deficits 
are not severe, and the age-dependent degeneration of BFCN are absent in these mice.  However, 
this does not mean that Ts1Cje is of no use, as comparison between other trisomic models can 
allow for the pinpointing of genes involved in some DS phenotypes.  For example, neuronal 
atrophy is absent in Ts1Cje and present in Ts65Dn, suggesting that the missing region, from APP 
to SOD1, is required for the pathology to develop (Sago et al., 1998).    
 The newest model mouse to emerge is from a group out of England. Tc1 (Tc = 
transchromosomic).Unlike the previously discussed models, this mouse carries an almost 
complete copy of human chromosome 21 (approximately 92% of all genes). It recapitulates 
almost all DS phenotypes including the heart defects seen in DS newborns (Galante et al., 2009). 
While this sounds like the ideal model, genetically speaking it’s identical to DS in humans, it has 
many weaknesses. For one, the coexistence of  human chromosome and human proteins in 
mouse environment can be problematic for interpretation, since mice and humans have various 
differences that underline development and aging. Further, a primary issue with  the Tc1 model 
is that the freely segregating HSA21 is not found in all tissues, making this more relevant to 
mosaic type of DS.   
The DS model we have chosen to use for our studies is the most widely used and studied 
DS mouse model: Ts(17
16
)65Dn mouse (Ts65Dn). This mouse carries a segmental trisomy,  
created by Davisson et al,. To create this mouse, testes of DBA/2J male mice were cesium 
irradiated and then  bred to C57BL/6J female mice (Lorenzi, Duvall, Cherry, Reeves, & Roper, 
2010). The resulting offspring that carried reciprocal translocations for Mmu16 were bred to 
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B6C3F1 mice (Davisson et al., 1993). This resulted in Ts65Dn heterozygote mice producing 
offspring with the small marker chromosome consisting of the telomeric Mmu16 attached to a 
Mmu17 centromere (Dierssen et al., 2001).  Ts65Dn is trisomic for roughly 104 genes (from App 
to Mx1) that are homologous to HSA21 and have be shown to be responsible for several DS 
phenotypes (Noemí Rueda et al., 2012). Phenotypes exhibited in Ts65Dn mice include 
developmental abnormalities, cognitive and neurological impairments, craniofacial 
abnormalities, and age-related deterioration of BFCNs (Roper, St John, Philip, Lawler, & 
Reeves, 2006).  Another characteristic of Ts65Dn is the increase in oxidative stress markers seen 
in young and old mice(Domenico et al., 2015).  What makes this model practical is that the mice 
survive live birth and age to adulthood allowing for postnatal research.  This allows researchers 
to study many aspects of DS such as the premature aging phenotype as well as the development 
of AD. Proliferation impairment was reported in cultured fibroblasts from newborn Ts65Dn. 
Ts65dn fibroblasts uptake of BrdUrd, a thymidine analogue that is incorporated by proliferating 
cells during the S-phase of cell cycle was reduced by 30%  (Contestabile et al., 2009).   The 
fibroblast also exhibited morphologic changes characteristic of senescent cells sush as enlarged, 
flattened shape and increase in number of SA-Beta Gal positive cells (Contestabile et al., 2009).  
In vivo studies also showed Ts65Dn mice having an impaired proliferation in skin collected from 
2 day old Ts65dn post BrdU injection (Contestabile et al., 2009).  These findings show a 
premature aging phenotype that mimics what has been reported in DS. As they age, they develop 
pathologies consistent with other age related disease such development of AD and increase 
incidence of lymphomas (Levine et al., 2009).   
Even so there are drawbacks associated with Ts65Dn model.  For one, male progeny are 
sterile thus expansion is dependent on female mice. Though most features of DS are 
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recapitulated, some are nonexistent, notable they do not exhibit the heart defects seen in DS. 
Also Ts65Dn is only a partial Mmu 16 Trisomy, accounting for approximately 60% of genes on 
HSA21. Despite these weaknesses, the advantages of the Ts65Dn model have been 
used/exploited for the study of cognitive impairment, AD, and aging in DS.  
Ms1Ts65 is a DS mouse model created by crossing Ts65Dn female (see below) and 
Ts1Cje male mice.  Ms1Ts65 mice have been very useful in separating out the effects of genes  
present in Ts65Dn but not Ts1Cje mice on DS phenotypes.  Comparison studies between 
Ts65Dn and Ms1Ts65have demonstrated that the Ts65Dn phenotypes, absent in other segmental 
models,  is most likely due to the interaction between the trisomic genes in the distal end of 
MMU 16 (Dierssen et al., 2001) On its own, the Ms1Ts65 model displays the fewest similarities 
to the DS phenotype when compared to other segmental trisomics models, though they  have 
been useful in allowing us to have a better understanding of the genes found in DS critical region 
(DSCR) and their role of these genes in some phenotypes of DS. 
4.4 Transgenic Mice  
 Despite the overwhelming advantage of full and partial Trisomy models, single gene 
mouse models overexpressing genes on HSA21 have also generated key findings in deciphering 
DS pathogenesis. We refer to these models as transgenic DS mice. The transgenic genes are 
believed to be important in driving DS phenotypes.  This type of model allows researchers to 
examine the role of one gene at a time in the complex phenotype of DS. Though they don’t 
recapitulate all DS traits, they do offer insight into role of single genes on development of DS.  
The Sod1 mouse was the first of these transgenic mice to be produced.  Superoxide dismutase 1 
(Cu-Zn), Sod1, is gene encoded on DSCR of HSA21 and MMU 16 is responsible for destroying 
free superoxide radicals by converting them to hydrogen peroxide (Florian L. Muller et al., 
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2007).  Transgenic mice over expressing Cu-Zn Sod1 show chronic oxidative stress as well as 
cognitive impairment (de Haan et al., 1995).  The chronic oxidative stress has been linked to 
accelerated aging of many tissues and organism as a whole.  Overexpression of SOD1 has been 
verified in many, but not all, tissues and cell lines of DS  (Campos & Casado, 2015).  
 The amyloid precursor protein (APP) transgenic model is predominately used in 
Alzheimer’s disease research.  The humanized APP mouse  is overexpressed through use of 
active promoters, allowing for overexpression of human APP in the mouse (Quon et al., 1991).  
In addition to APP overexpressing models, mutants mimicking human APP mutations have also 
been created, and have been useful in identifying key human APP mutation that may lead to  
Alzheimer’s(Lott et al., 2006). Many of these transgenic models showed promising results but 
lacked full AD neuropathology, demonstrating pretty effectively that APP overexpression or 
mutation is not sufficient for development of AD.  In 1995 Games et al. used platelet-derived 
growth factor promoter, (PDGF)-B to generate a transgenic mouse model overexpressing mutant  
human APP ( with valine at residue 717 substituted by phenylalanine) (Games et al., 1995).  This 
model, unlike the previous models, exhibited AD neuropathology, including amyloid beta 
deposition, dystrophic neuritic components, gloiis and loss of synaptic density (Games et al., 
1995). Crosses of SOD1and APP mice revealed to be more useful than their standalone models 
in elucidating AD neuropathology.  As stated earlier, most transgenic models of APP lacked the 
formation of beta amyloid deposits, while SOD1-APP model recapuliated this phenomenon seen 
in DS individuals with AD.  Multiple models of APP are actively used today in developing 
therapeutics to treat not ony eldery AD patients but also DS individual with AD.  
 DYRK1A is a nuclear serine/threonine kinase that is localized to  HSA21 and 
isoverexpressed in several  DS tissues (Altafaj et al., 2001). DYRK1A is thought by many to be a 
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key candidate driving nervous system alterations in DS.  Altafaj et al., created a transgenic mice 
overexpressing DYRK1A under the control of the inducible sheep metallothionein-Ia (sMT-Ia) 
promoter (Altafaj et al., 2001). TgDyrk1A mice exhibit DS phenotypes that include neuromotor 
development, hyperactivity, and significant impairment in spatial learning and memory (Altafaj 
et al., 2001).   Researchers trying to detect the cellular and molecular events that lead to the 
phenotype seen in TgDyrk1A mice and other DS models were able to demonstrate that Dryk1A 
alters the timing of neural cell proliferation and differentiation (Yabut, Domogauer, & 
D'Arcangelo, 2010).  Additional studies using more sophisticated mice models of Dyrk1a will 
allow a better understanding of the role of this gene on DS phenotype.  
ETS2 is a member of the Ets family of transcription factors and is known to activate 
apoptosis in DS tissues.  It is located within the crictial region of DS on HSA2.  DS neuronal 
cultures exhibit a fivefold increase in ETS2 expression (Rueda et al 2012). ETS2 has important 
roles in cancer, bone development and immune responses (Wolvetang et al., 2003).   It should be 
noted that the overexpression of ETS2  is thought to be key  in the low incidence of solid tumors 
in DS. This is believed to be due to its role in regulation of key apoptotic genes (N. Rueda, 
Florez, & Martinez-Cue, 2013).  Like the other transgenic DS models, tgETS2 displays DS 
phenotypes such as smaller thymus and lymphocyte abnormalities (Wolvetang et al., 2003).   
ETS2 mice also display increased neural cell death, which leads to suggestion that  it plays a 
major role in the neural degeneration seen in many mouse models of DS as well as inDS 
individuals (Rueda et al 2013) 
S100 calcium binding protein  (S100) is found to affect the nervous system, 
specifically the glial cells.  Transgenic S100 mice were development by placing the human S-
100β gene into the mouse genome, under control of its own regulating elements (Friend et al., 
69 
 
 
1992).  Studies by Whitaker-Azmitia et al. show transgenic mice overexpressingS-100β  have 
abnormal neuronal morphology as well as accelerated aging (Whitaker-Azmitia et al., 1997).  
When comparing the transgenic mice to control,  young mice had increased density of dendrites 
and that as they aged they exhibit a significant loss of dendrite density, suggesting an important 
role of S100B in AD development in DS individuals (Whitaker-Azmitia et al., 1997).  
4.5 Materials and Methods 
Animals: Segmental trisomy 16 (Ts65Dn) mice were obtained by mating Ts65Dn females 
(B6EiC3H – a/ATs65Dn) with (C57BL/6JEi × C3H/HeJ)F1 (JAX # JR1875) males. Ts65Dn 
mice were thus maintained on the B6/C3H background (Davisson et al., 1993).
  
Experimental 
male mice were housed at the Eleanor Roosevelt Institute at the University of Denver. Ts65Dn 
was genotyped using a quantitative PCR protocol. The technique is based on the DDCT 
calculation method between a control gene present in two copies (ApoB) and a target gene 
present in three copies (Mx1) (Lorenzi et al., 2010).  Mice were organized into three cohorts (16 
week, 32 week, and 48 week) . A total of 63 mice were placed in three cohorts: 16 week (n=23) 
with 10 Ts65Dn and 13 WT, 32 week (n=20) with 9 Ts65Dn and 11 WT and 48 week (n=20) 
with 10 Ts65Dn and 10 WT. In each cohort, there were 9-11 mice in each group (~10 WT and 
10 Ts65Dn).  Animals were maintained in a 12:12-hour light/dark schedule (lights on at 7 AM) 
with ad libitum access to food and water. The cross-sectional pathological analysis of tissues 
from trisomic and disomic mice was carried out by Dr. Yuji Ikeno at UTHSCSA.   
 
        16 weeks (4 months)  32 weeks (8 months)    48 weeks (12 months) 
 
 
13 WT 10 WT 10 WT 10 Ts65dn 9 Ts65Dn 10 Ts65Dn 
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Analysis of Pathology:   The mice were necropsied for gross pathological lesions. Organs and 
tissues were excised and preserved in 10% buffered formalin. The fixed tissues were processed 
conventionally, embedded in paraffin, sectioned at 5 μm, and stained with hematoxylin and eosin 
(Zhang et al., 2009). For each mouse, a list of pathological lesions that included both neoplastic 
and non-neoplastic diseases was constructed. Based on these histopathological data, the tumor 
burden, disease burden, and severity of each lesion in each mouse were assessed (Bronson & 
Lipman, 1991). The severity of neoplastic  lesions was assessed using the grading system 
previously described (Ikeno, Bronson, Hubbard, Lee, & Bartke, 2003).  
MicroRNA 155 Expression:  Total RNAs was isolated from the brain, testes, heart, kidney, 
lung and liver of Ts65Dn and WT mice using Trizol method.  A total of 50 ng of total RNA was 
used for reverse transcription (RT) reaction. RT reactions were realized with 0.15 μL dNTP, 1.5 
μL buffer (10x), 9 μL RNAse-free water, 0.2 μL RNAse inhibitor, 1 μL multiscribe Reverse 
Transcriptase, and 3 μL of specific miR-155  RT primers (Applied Biosystems ). RT reactions 
were set at 16°C for 30 minutes, 42°C for 30 minutes, and 85°C for 5 minutes using a BioRad 
thermal cycler . The TaqMan  miR-155 assay (Applied Biosystems ) was used to quantify miR-
155. 5 μL of RT reactions was mixed with 10 μL of TaqMan Universal PCR master mix (2x, 
(Applied Biosystems)) 4 μL of RNAse-free water, and 1 μL of TaqMan miRNA Assay (20X , 
(Applied Biosystems)). Quantitative real-time PCR analysis was performed using the 
LightCycler 480 (Roche) at 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds 
and 60°C for 60 seconds.  Sno202 (Applied Biosystems), a noncoding RNA, was used as 
endogenous control.  
Expression analysis: Total RNAs were isolated from the brain, testes, heart, kidney, lung and 
liver of Ts65Dn and WT mice using Trizol method. cDNA was synthesized, as described 
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previously (Cabelof et al. 2006a), from 2µg RNA using random hexamer primers and purified 
with the QIAquick PCR Purification columns (Qiagen, Valencia, CA). Transcripts were 
amplified and quantitated with a LightCycler Real Time PCR machine (Roche). PCR reactions 
contained 2µl purified cDNA, 0.5 µM of each sense and antisense primer, and 2µl FastStart 
DNA Master SYBR Green I enzyme-SYBR reaction mix (Roche). For all amplifications, PCR 
conditions consisted of an initial denaturation step at 99°C for 10 min, followed by 35–45 cycles 
at 96°C for 10s, primer specific annealing temperatures for 10s, and elongation at 72°C for 5s. 
Melting curves from 40°C to 99°C confirmed specificity. External standards were prepared for 
all genes from cDNA amplicons cloned into pCRII TOPO cloning vector (Invitrogen). All 
transcripts were quantitated and normalized to GAPDH or RPL4 expression. Primer sequences 
are detailed in Table 4.4. 
Data Analysis: 
Results are expressed as mean ± SEM analyzed and were analyzed using Student’s t-test. 
Statistical comparisons between groups were conducted using one-way ANOVA, using 
GraphPad Prism 5.0 (Graph Pad Software, La Jolla, CA). Values of p < 0.05 were considered 
statistically significant and individual p-values are shown in the figures. 
4.6 Results 
Body and Organ Weight of Ts65Dn and WT Mice at 16, 32 and 48 weeks. 
We evaluated the body weight of Ts65Dn and WT controls with in the three age groups.   
The body weight of both Ts65Dn and WT mice increased steadily and almost linearly with age 
(Figure 4.6.1). A comparison of Ts65Dn and WT mice showed that Ts65Dn mice had a smaller 
body weight than the WT counterparts (Figure 4.6.1).  This difference persisted in three age 
groups. Evaluation of tissues showed some differences. Lung of Ts65Dn at 16 week were 
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significantly smaller but with age this difference is lost (Figure 4.6.2). The most dramatic 
difference was in testes size. Ts65Dn testes were significantly smaller than their WT controls 
and this difference persisted in all three aged cohorts (Figure 4.6.3).These results are consistent 
with has been reported earlier and is has been linked to male sterility that is reported in Ts65Dn 
(Davission et al., 2007)   Kidney and brain did not show any difference between the two 
genotypes (Figure 4.6.4 and 4.6.7).  Heart and liver of Ts65Dn mice at 16 week were 
significantly smaller than WT (Figure 4.6.5 and 4.6.6).These results are consistent with Fuchs et 
al study. They showed that not only was heart and liver smaller, there was also an impaired 
proliferation as assayed by BrdU  (Fuchs et al., 2012). At 32 and 48 weeks a trend of small size 
was seen but was not significantly different from WT. Interestingly, we did not see any 
differences in spleen or thymus which have been shown to be underdeveloped in Ts65Dn 
((Lorenzo, Shatynski, Clark, Yarowsky, & Williams, 2013). Furth more, no differences were 
seen in fat tissues between Ts65Dn and WT (data not shown).  
 Neoplastic incidences  
It has been suggested that gene dosage imbalances caused by the presence of an extra 
copy of chromosome 21 may be protective against the development of certain malignancies in 
DS individuals. The low incidence of solid tumors in DS individuals has been well documented 
in population studies worldwide; with the exception to this is testicular cancer (Uppal et al., 
2015). Though the incidence of solid tumors is low, DS children have a 10- to 20-fold increased 
risk of developing acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) 
compared with non-DS children (Hermon et al., 2001).  The mouse models of DS have shown 
similar results with respect to low incidence of solid tumors and increase in malignant lymphoma 
(Patterson & Cabelof, 2012). In our study we found that Ts65Dn spleen had an increase minimal 
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and mild lymphoma at 16 week and 32 week (Figure 4.6.17). By 48 weeks, the difference 
between ts65dn and WT was lost. 20% of 16 week old Ts6d5n mice also exhibited minimal 
invasive lymphoma in lung and stomach (Figure4.6.18 and 4.6.19). Lungs of Ts65Dn mice also 
showed increase in alveolar/bronchiolar adenoma incidence which was absent in WT mice 
(Figure 4.6.18).  In 48 week old Ts65Dn, the incidence of invasive lymphoma increased for both 
stomach and intestine (Figure 4.6.20).  Our results are in line with that Levine et al., showed in 
three different mouse models of DS including Ts65dn. The absence of solid tumors in our 
cohorts of Ts65Dn supports the continued use of this model in studying DS malignances.  
 p16 expression on peripheral tissues 
One of the most commonly used in vivo markers of senescence is the expression of 
p16INK4A, a selective inhibitor of cyclin D-dependent CDK4 and CDK6 (Y. Liu et al., 2009). 
The expression of p16 increases with age normally and in the response to stress (Baker et al., 
2011). In our study we sought to know if Ts65Dn tissues had increase in p16 expression. In all of 
tissues evaluated, we did not see a significant increase of p16 in either WT or Ts65Dn mice.  
Liver and Lung of Ts65dn showed a slight increase at 16 weeks that was not statistical 
significant (Figure 4.6.11 and 4.6.13). Testes did show an increase in p16 with age independent 
of genotype differences (Figure 4.6.16). Our results further support previous work that p16 is 
only detectable in advanced age and is undetectable or very low in most adult 
tissues(Krishnamurthy et al., 2004). It is possible that 48 week (12 months) old mice are too 
young to display any aging phenotype regardless of genotype.   
Expression of DNA polymerase beta (Polβ)  
 Evaluation of DNA repair capacity or expression levels of the main players has not been 
extensively studied in Ts65Dn. DS individuals have been shown to have a defective DNA repair 
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(Druzhyna et al., 1998; Necchi et al., 2015; Pincheira, Rodriguez, Bravo, Navarrete, & Lopez-
Saez, 1994; Weirich-Schwaiger et al., 1994) and in particular have reduced expression and 
activity of POLΒ(Cabelof et al., 2009; Raji & Rao, 1998).  Our objective was to look at the 
expression of Polβ  in several tissues of Ts65Dn. In the tissues assessed (liver, lung, kidney, 
testes, brain, heart, and skin), only testes showed a reduction of Polβ. In the 16 week old group, 
the Ts65Dn mice showed a significant decrease in Polβ compared to control littermates (Figure 
4.6.7, p<0.01).These findings are notable as testes are the only tissues to develop cancer in DS.  
Brain of Ts6dn at 16 week revealed a trend of downregulation of Polβ that was not statistically 
significant. Skin also showed reduced Polβ expression at 48 weeks though it was not significant 
(Figure4.6.10). Unlike DS, the Ts65Dn mouse did not show a progressive downregulation of 
Polβ over time in the tissues tested. The next step is to look at accumulation of repair 
intermediates, such as SSB and DSB, as markers of repair capacity. A recent study revealed 
hematopoietic stem cells (HSCs) of Ts65Dn have an accumulation of DSBs at baseline and that 
these HSCs are defective in repairing radiation-induced DSBs(Wang et al., 2016). These results 
allows us to anticipate that Ts65Dn will show an increase in DSBs as they age. 
4.7 Discussion 
In the 1970s we saw the production of the first model of DS and it had promising results. 
Many years later, we still do not have a perfect animal model but a compilation of data from 
distinct models has given us great insight into DS pathogenesis. The limitations with many of the 
in elucidating the genetic sources of the DS phenotype have been described above.  In addition to 
genetic influences, we have not discussed potential epigenetic factors that may also account for 
pathogenesis in DS, as well as the many difference between mice and humans (Gunter & Dhand, 
2002).  
75 
 
 
In our studies, we utilize the model considered by most to be the most inclusive model of 
DS. Though the model lacks certain cardiovascular anomalies it is still a very useful model for 
studying molecular mechanism of DS. Studies focusing on aging traits have revealed Ts65Dn 
mice exhibit muscle weakness and motor alterations (sarcopenia) at  12 months and 19 months 
(Cisterna, Costanzo, Scherini, Zancanaro, & Malatesta, 2013).  Systemic pathology in aged 
Ts65Dn (8 to 24 months) indicated a significant increase in prevalence of adenocarcinoma 
/lymphoma (Levine et al., 2009).  Our study showed that Ts65Dn does mimic some of DS traits 
such as increase in lymphoma incidence and low incidences of solid tumors. We failed to find 
any solid tumors in the three cohorts evaluated. Counter to our hypothesis, we did not see any 
changes in expression of p16 or Polβ over time in most tissues, with the one exception being 
testes which showed an early significant downregulation of POLB (figure 2.1) and a steady 
increase of p16 over time (figure 3.6).  Screening for other markers of aging such as SA-beta gal 
and SASP in this model will allow us to consider whether continued use of this model in aging 
research is beneficial.  
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Mouse Model Type of Model DS Features 
Ts16 Trisomic - impaired learning 
- increased oxaditive stress in 
utero 
-mitochondrial dysfunction 
Ts65Dn Segmental Trisomy -developmental delay 
-hyperactivity, 
-craniofacial dysmorphology  
-impaired learning 
-behavior deficits 
-Reduced density of 
cerebellar granule cells 
- oxidative stress markers in 
young and old Ts65Dn mice 
Ts1Cje Segmental Trisomy -impaired learning  and 
memory 
-Reduced density of 
cerebellar granule cells 
-hypoplasia of the cerebellum 
and enlarged ventricles  
Ms1Ts65 Segmental Trisomy -Moderate reduction in 
density of cerebellar granule 
cells 
-moderate impaired learning 
and memory. 
Ts1Rhr Segmental Trisomy -impaired learning  and 
memory 
-moderate craniofacial 
dysmorphology   
Tc1 “full Trisomy” -cardiac malformations 
-developmental delay 
-hyperactivity, 
-craniofacial dysmorphology  
-impaired learning 
 
Table 4.2:  Summary of segmental trisomy mouse models and features of Down syndrome that 
have been documented in each model. 
 
 
 
 
 
77 
 
 
Mouse Model Type of Model DS Features 
Dyrk1A BAC Transgenic -Abnormal brain structure 
and locomotors behavior 
SOD1 Transgenic -chronic oxidative stress 
-Abnormal neuromuscular 
junction  
-decreased plasma serotonin 
level  
 
APP Transgenic -Dystrophic neuritis 
associated with congophilic 
plaques 
ETS2 Transgenic -Skeletal abnormalities 
particularly craniofacial 
abnormalities 
 -brachycephaly 
S100β Transgenic -Abnormal dendritic 
development 
 
Table 4.3:  Summary of transgenic Mouse models 
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Gene Sense primer 5′–3′ Anti-sense primer 5′–3' 
Mouse   
p16 UPL probe #91 aatctccgcgaggaaagc Gtctgcagcggactccat 
B-pol (exon 12–13) agcgagaaggatggaaaggaa Cgtgcgctctcatgttcttat 
Housekeeping genes (mouse)   
Gapdh aggtcggtgtgaacggatttg Tgtagaccatgtagttgaggtca 
Rpl4 ccgtcccctcatatcggtgta Gcatagggctgtctgttgttttt 
Rpl4 UPL probe # 75 tggtggttgaagataaggttga Ccaagctttgagtttcttgagc 
 
Table 4.4: Primer sequences 
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Figure 4.6.0: Ts65Dn are smaller than WT controls.  These data were obtained from three 
cohorts (16, 32, and 48 week) Ts65Dn and WT mice. Body weight (n = 23, 20, and 20 for 16, 32 
and 48 week mice, respectively). The data shown is from male mice only.  The data are 
expressed as the mean ± SEM.  
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Figure 4.6.1: Liver wet weights in Ts65dn (DS) and WT (NDS). These data were obtained 
from three cohorts (16, 32, and 48 week) Ts65Dn and WT mice. Body weight and tissue wet 
weight (n = 23, 21, and 20 for 16, 32 and 48 week mice, respectively). The data shown is from 
male mice only.  The data are expressed as the mean ± SEM 
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Figure 4.6.2: Weight of Lung in three cohorts. These data were obtained from three cohorts 
(16, 32, and 48 week) Ts65Dn and WT mice. Tissue wet weight (n = 23, 21, and 20 for 16, 32 
and 48 week mice, respectively). The data shown is from male mice only.  The data are 
expressed as the mean ± SEM  
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Figure 4.6.3: Ts65Dn mice have underdeveloped Testes.  Both left and right testes in Ts65Dn 
mice were significantly smaller in the three age groups. A total of  n = 23, 21, and 20 for 16, 32 
and 48 week mice, respectively). The data are expressed as the mean ± SEM  
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Figure 4.6.4: Kidney weight did not differ. These data were obtained from three cohorts (16, 
32, and 48 week) Ts65Dn and WT mice. Body weight and tissue wet weight (n = 23, 21, and 20 
for 16, 32 and 48 week mice, respectively). The data shown is from male mice only.  The data 
are expressed as the mean ± SEM  
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Figure 4.6.5: Ts65Dn heart seems to be smaller than WT. These data were obtained from 
three cohorts (16, 32, and 48 week) Ts65Dn and WT mice. Body weight and tissue wet weight (n 
= 23, 21, and 20 for 16, 32 and 48 week mice, respectively). The data shown is from male mice 
only.  The data are expressed as the mean ± SEM  
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Figure 4.6.6: No difference was seen in Brain weight. These data were obtained from three 
cohorts (16, 32, and 48 week) Ts65Dn and WT mice. Body weight and tissue wet weight (n = 
23, 21, and 20 for 16, 32 and 48 week mice, respectively). The data shown is from male mice 
only.  The data are expressed as the mean ± SEM  
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Figure 4.6.7: PolB expression in Ts65Dn mice tissues at 16 week.  cDNAs were prepared 
from RNA isolated from  tissues of  Ts65Dn (n=10) and control littermates (n=13) mice from 
three cohorts ( 16, 32, and 48 week). PolB transcript levels were determined by real time RT-
PCR analysis and normalized to Rpl4. Data are presented as mean ± SEM. 
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Figure 4.6.8:  PolB expression in Ts65Dn mice tissues.  cDNAs were prepared from RNA 
isolated from  tissues of  Ts65Dn (n=10) and control littermates (n=10). PolB transcript levels 
were determined by real time RT-PCR analysis and normalized to Rpl4. Data are presented as 
mean ± SEM. 
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Figure 4.6.9: PolB expression in Ts65Dn mice tissues.  cDNAs were prepared from RNA 
isolated from  tissues of  Ts65Dn (n=9) and control littermates (n=10) mice from three cohorts ( 
16, 32, and 48 week). PolB transcript levels were determined by real time RT-PCR analysis and 
normalized to Rpl4. Data are presented as mean ± SEM 
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Figure 4.6.10:  PolB expression in Ts65Dn Skin.  cDNAs were prepared from RNA isolated 
from  tissues of  Ts65Dn (n=9) and control littermates (n=10) mice from three cohorts ( 16, 32, 
and 48 week). PolB transcript levels were determined by real time RT-PCR analysis and 
normalized to Rpl4. Data are presented as mean ± SEM 
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Figure 4.6.11: p16 expression in Ts65Dn Tissues: cDNAs were prepared from RNA isolated 
from  tissues of  Ts65Dn ( 9-11 mice in each group) and control littermates mice from three 
cohorts(16, 32, and 48 week). PolB transcript levels were determined by real time RT-PCR 
analysis and normalized to Rpl4. Data are presented as mean ± SEM. 
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Figure 4.6.12 : p16 expression in Ts65Dn Tissues: cDNAs were prepared from RNA isolated 
from  tissues of  Ts65Dn ( 9-11 mice in each group) and control littermates mice from three 
cohorts(16, 32, and 48 week). PolB transcript levels were determined by real time RT-PCR 
analysis and normalized to Rpl4. Data are presented as mean ± SEM. 
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Figure 4.6.13: p16 expression in Ts65Dn Tissues: cDNAs were prepared from RNA isolated 
from  tissues of  Ts65Dn ( 9-11 mice in each group) and control littermates mice from three 
cohorts(16, 32, and 48 week). PolB transcript levels were determined by real time RT-PCR 
analysis and normalized to Rpl4. Data are presented as mean ± SEM. 
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Figure 4.6.14: p16 expression in Ts65Dn Tissues: cDNAs were prepared from RNA isolated 
from  tissues of  Ts65Dn ( 9-11 mice in each group) and control littermates mice from three 
cohorts(16, 32, and 48 week). PolB transcript levels were determined by real time RT-PCR 
analysis and normalized to Rpl4. Data are presented as mean ± SEM. 
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Figure 4.6.15: p16 expression in Ts65Dn Tissues: cDNAs were prepared from RNA isolated 
from  tissues of  Ts65Dn ( 9-11 mice in each group) and control littermates mice from three 
cohorts(16, 32, and 48 week). PolB transcript levels were determined by real time RT-PCR 
analysis and normalized to Rpl4. Data are presented as mean ± SEM. 
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Figure 4.6.16: p16 expression in Ts65Dn Tissues: cDNAs were prepared from RNA isolated 
from  tissues of  Ts65Dn ( 9-11 mice in each group) and control littermates mice from three 
cohorts(16, 32, and 48 week). PolB transcript levels were determined by real time RT-PCR 
analysis and normalized to Rpl4. Data are presented as mean ± SEM. 
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Age (weeks)  
Minimal Invasive 
Lymphoma   
Mild Invasive 
Lymphoma 
16 
WT (n=13) 39% 0% 
Ts65dn (n=10) 80% 0% 
32 
WT (n=10) 55% 0% 
Ts65dn (n=9) 67% 11% 
48 
WT (n=10) 60% 20% 
Ts65dn (n=10) 80% 0% 
 
Figure 4.6.17: Incidence of lymphoma in Ts65Dn Spleen. Spleen was excised and preserved 
in 10% buffered formalin. It was sectioned at 5 μm, and stained with H&E.  Grading of 
neoplastic lesions as described in Materials and Methods was  completed on  Ts65Dn and WT 
mice terminated at each of the three time points (16, 32 and 48 weeks). Percentage of mice with 
lesions is presented.   
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Figure 4.6.18: Incidence of malignant tumors of lung in Ts65Dn. Lung was excised and 
preserved in 10% buffered formalin. It was sectioned at 5 μm, and stained with H&E.  Grading 
of neoplastic lesions as described in Materials and Methods was  completed on  Ts65Dn and WT 
mice terminated at each of the three time points (16, 32 and 48 weeks). Percentage of mice with 
lesions is presented 
 
 
 
 
 
 
Age (weeks)  
Minimal Invasive 
Lymphoma   
lymphocytic 
infiltrate 
alveolar/bronchiolar 
adenoma 
16     
WT (n=13) 0% 0% 0% 
Ts65dn 
(n=10) 20% 0% 0% 
32    
  WT (n=10) 9% 9% 0% 
Ts65dn (n=9) 11% 11% 0% 
48  
   WT (n=10) 10% 0% 0% 
Ts65dn 
(n=10) 20% 20%                         10% 
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Figure 4.6.19: Incidence of lymphoma in stomach of Ts65Dn. Stomach was excised and 
preserved in 10% buffered formalin. It was sectioned at 5 μm, and stained with H&E.  Grading 
of neoplastic lesions as described in Materials and Methods was  completed on  Ts65Dn and WT 
mice terminated at each of the three time points (16, 32 and 48 weeks). Percentage of mice with 
lesions is presented 
 
 
 
 
 
 
 
 
 
Age (weeks)  Minimal Invasive Lymphoma   Mild Invasive Lymphoma 
16    
WT (n=13) 0% 0% 
Ts65dn (n=10) 10% 20% 
32      
WT (n=10) 0% 0% 
Ts65dn (n=9) 0% 0% 
48      
WT (n=10) 0% 0% 
Ts65dn (n=10) 0% 20% 
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Age 
(weeks)  
Minimal Invasive 
Lymphoma   
Mild Invasive 
Lymphoma 
Minimal 
lymphocytic 
infiltrate  
Mild 
lymphocytic 
infiltrate  
16  
WT (n=13) 46% 15% 15% 0% 
Ts65dn 
(n=10) 40% 30% 0% 0% 
32    
 
    
WT (n=10) 45% 0% 18% 9% 
Ts65dn 
(n=9) 56% 0% 0% 0% 
48    
 
    
WT (n=10) 20% 10% 10% 0% 
Ts65dn 
(n=10) 40% 0% 20% 0% 
 
Figure 4.6.20: Incidence of lymphoma in Intestine of Ts65Dn. Intestine was excised and 
preserved in 10% buffered formalin. It was sectioned at 5 μm, and stained with H&E.  Grading 
of neoplastic lesions as described in Materials and Methods was  completed on  Ts65Dn and WT 
mice terminated at each of the three time points (16, 32 and 48 weeks). Percentage of mice with 
lesions is presented 
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DS Ts65Dn Ts1Cje Ms1Ts65 Ts1Rhr 
Motor skills Delayed 
acquisition 
Delayed 
acquisition 
   
Motor coordination Impaired Impaired    
Activity and attention Reduced 
attention 
Hyperactivity and 
reduced attention 
Normal activity Normal activity Normal activity 
Spatial learning and memory Impaired Impaired Impaired Impaired  
Working and reference 
memory 
Impaired Impaired    
Novel object recognition  Impaired   Impaired 
Brain volume 
  
Reduced during 
the embryonic 
period 
Reduced during 
the embryonic 
period 
Reduced 
Neuronal density 
  
Reduced Not affected 
 
Cerebellar volume 
   
Reduced Not affected 
Cerebellar neuronal density 
   
Reduced Reduced 
Proliferation  Impaired Impaired    
DNA repair capacity Defective to 
extent 
evaluated  
Defective to 
extent evaluated 
   
 
Table 4.7.1:  Summary of Segmental trisomy Mouse models. 
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CHAPTER 5: Conclusion and Future directions 
 
The study sought to answer the following two questions: 
 Is the premature aging seen in DS a result of PolB downregulation? 
 Is miR-155 involved in down regulations of POLB and DNA repair capacity 
overall?  
The study set out to explore the possible role of POLB in the premature aging phenotype 
of Down syndrome. Premature aging has been demonstrated in numerous biological systems in 
individuals with DS: cognition, the auditory system, the skin, brain structure, the immune 
system, and the olfactory system. Additionally, it has been reported that persons with DS show 
an earlier appearance of various biomarkers associated with aging, including DNA damage 
accumulation and chromosomal sensitivity to mutagens. Nearly all premature aging syndromes 
(including Werner, Rothmund-Thomson and Cockayne syndromes, trichothiodystrophy and 
ataxia telangiectasia) have been characterized by DNA repair defects, yet no specific defect has 
yet been identified for DS(Brosh & Bohr, 2007).  
The problem with firmly establishing the role of a DNA repair defect, in particular 
POLB, in premature aging of DS is that DS is a chromosomal disorder and not monogenic. Still, 
several studies have shown that POLB is downregulated in DS, while other polymerases are 
unaffected (Cabelof et al., 2009; Raji & Rao, 1998). POLB is the best candidate for the 
premature aging phenotype of DS, since it has been shown to be reduced with age in multiple 
models (Krishna et al., 2005; Patterson & Cabelof, 2012; Raji & Rao, 1998; Rao, 2007; Rao et 
al., 2001; Swain & Rao, 2012; Sykora et al., 2015; Vyjayanti et al., 2012).  
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Studies conducted in this thesis further provide support that reduced POLB is causative in 
premature aging.  My data from chapter 2 clearly demonstrated that reduced POLB expression 
results in premature senescence as well an accumulation of DSBs. To confirm role of POLB in 
premature senescence, I show primary PolB null MEFs also have increase in senescence 
markers, p16 expression and SA-beta gal staining, as well as DSBs.  Another observation 
generated by the work on PolB null cells is that PolB is upregulated by hydroxyurea and that 
DSBs generate in these cells in absence of any exogenous damage. It would be very interesting 
to investigate the mechanism of hydroxyurea mandated upregulation of PolB since POLB 
upregulation is common in several cancers and hydroxyurea is a common antineoplastic 
chemotherapy drug(Illuzzi & Wilson, 2012).  
Establishing that POLB down regulation correlates with premature aging was the primary 
objective of this thesis.  My data in chapter 2 led to further exploration of the cause of POLB 
downregulation in DS. The hypothesis was that PolB inhibition was induced by chromosome 21-
linked miRNA overexpression. miR-155 is one of five microRNAs on HSA21, which has been 
shown to modulate DNA repair. miR-155 role in mismatch repair is well establish and has been 
linked to increase in genomic instability in several cancers. However, the mutational specificities 
of both 155 overexpression and Down syndrome are not consistent with a MMR defect (Cabelof 
et al., 2009; Czochor et al., 2016; Finette et al., 1998). 
 My search of possible link between miR-155 and PolB revealed that Creb1, transcription 
factor of PolB, is a direct target of mir-155.  Validation studies demonstrated that miR-155 
overexpression results in reduced protein levels of creb1 and its targets. Researchers have long 
established the importance of Creb1 in PolB expression. With that, I anticipated that mir-155 
would cause low creb1 resulting in low PolB. Data from chapter 3 demonstrated just that.  PolB 
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promoter activity in cells that I engineered to over express miR-155 was significantly decrease 
compared to empty (null) vector.  Creb1 and PolB protein levels were also significantly reduced. 
My work only shows the effect of miR-155 in the absence of any damaging agents. It would be 
interesting to investigate the promoter inducibility by cytotoxic agents such as: MMS, H2O2, and 
methotrexate. An alternative hypothesis to explain PolB downregulation is accumulation of loss 
of function mutations on the promoter. Sequencing the PolB promoter in DS samples of varying 
ages would also be interesting. My data shows that DS cells have an attenuated response in 
presence of DNA damaging agents.   
 Over the years, studies have emerged to show that miR-155 is an important regulator of 
DNA repair. On the other hand, DNA damage response (DDR) in DS, has not been extensively 
studied and thus provides obvious issue when studying DNA repair in these individuals. Is the 
defect in DS a response or repair impairment? The research thus far does not present a clear 
answer.  A recent study suggests that miR-155 is regulating both the DDR and several repair 
pathways (Czochor et al., 2016). Interestingly, they show that regulation is via the transcription 
factor, FOXO3a. They show that miR-155 overexpression results in reduced FOXO3a protein 
and this leads to inhibition of HR and an upregulation of the error prone NHEJ. But FOXO3a is 
also a potent activator of BER via Gadd45a. These findings provide an alternative mechanism of 
how miR-155 could be inhibiting PolB independently of Creb1. Typically FOXO3a would 
activate Gadd45a in response to DNA damage, and in turn Gadd45a activates recruitment of 
BER genes via PCNA (Gutierrez-Mariscal et al., 2014). As described in diagram 5.1.1, I’m 
proposing that miR-155 may be regulating POLB by two distinct mechanisms: directly, via 
Creb1-induced inhibition, and indirectly via FOXO3a.  My proteomic data in chapter 3 provides 
support or both proposed models,  as we found that several BER genes are affected by miR-155.  
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Figure 5.1.1: The proposed mechanism by which miR-155 regulates PolB.  
The primary consequence of premature cellular senescence is the loss of proliferation 
which can be detrimental to survival of the organism.  Another important effect is secretion of 
factors that alter the tissue microenvironment.  Recent studies on senescence-associated secretory 
phenotype (SASP) of senescent cells revealed the potential of these secretions to initiate 
tumorigenesis(Taguchi et al., 2000) . High Mobility Group Box 1 protein (HMGB1) is one of 
many markers in the SASP. Exocytosis of HMGB1 enhances pro-inflammatory activity of 
cytokines. Several studies showed that senescent cells secrete HMGB1, which in turn recruits 
and activates cells from the innate immune system to clear senescent cells (Schlueter et al., 
2005).  Others showed that extracellular HMGB1 protein may be promoting cancer and 
metastatic progression (Sha, Zmijewski, Xu, & Abraham, 2008). HMGB1 is being used in 
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combination with p16 and SA-beta gal staining as markers of in vitro senescence. I have 
preliminary data on HMGB1 in our DS and PolB null cells that suggest that under both 
conditions, HMBB1 is extruded from the nucleus: an indicator of senescence. Early passage 
PolB cells show HMGB1 localized to nucleus while late passage cells show cytoplasmic 
localization. The DS fibroblast show the delocalization from nucleus to cytoplasm is occurring at 
earlier passage than their matched controls. Further investigation into the SASP both in the 
absence of POLB and in DS could provide great insight into the role of these factors in the DS 
phenotype.  One can speculate that the increase in age dependent lymphomas in DS might be due 
to SASP of the senescent cells that provide the proper microenvironment for tumorigenesis.  
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ABSTRACT 
INVESTIGATING THE ROLE OF DNA POLYMERASE BETA IN THE AGING 
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Down syndrome (DS) is a chromosomal condition characterized by accelerated aging that 
has yet to be directly linked to a DNA repair defect. Reduced PolB and unrepaired damage from 
oxidative stress observed in DS, point toward defective base excision repair (BER). In this study, 
we report that low PolB transcript correlates with increased markers of senescence.  The gene 
dosage effect of Trisomy 21 is likely the source for PolB downregulation. We show that the 
HSA21-localized miR-155 overexpression correlates with a decrease in Creb1 and PolB, thus 
establishing a putative regulatory pathway. Data from the DS mouse model, Ts65Dn, reveal low 
incidence of solid tumors consistent with clinical observations. Our findings establish Polβ as a 
causative factor of senescence, suggesting that base excision repair is one of the processes 
driving aging in Down syndrome. 
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